U.S. patent application number 13/030551 was filed with the patent office on 2011-10-20 for immunocompatible amniotic membrane products.
Invention is credited to Alla Danilkovitch, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi, Samson Tom, Dana Yoo.
Application Number | 20110256202 13/030551 |
Document ID | / |
Family ID | 44476694 |
Filed Date | 2011-10-20 |
United States Patent
Application |
20110256202 |
Kind Code |
A1 |
Tom; Samson ; et
al. |
October 20, 2011 |
IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS
Abstract
Provided herein is a placental product comprising an
immunocompatible amniotic membrane. Such placental products can be
cryopreserved and contain viable therapeutic cells after thawing.
The placental product of the present invention is useful in
treating a patient with a tissue injury (e.g. wound or burn) by
applying the placental product to the injury. Similar application
is useful with ligament and tendon repair and for engraftment
procedures such as bone engraftment.
Inventors: |
Tom; Samson; (Baltimore,
MD) ; Danilkovitch; Alla; (Columbia, MD) ;
Yoo; Dana; (Falls Church, VA) ; Jansen; Timothy;
(Baltimore, MD) ; Kuang; Jin-Qiang; (Woodstock,
MD) ; Marconi; Jennifer Michelle; (Glen Burnie,
MD) |
Family ID: |
44476694 |
Appl. No.: |
13/030551 |
Filed: |
February 18, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61338464 |
Feb 18, 2010 |
|
|
|
61338489 |
Feb 18, 2010 |
|
|
|
61369562 |
Jul 30, 2010 |
|
|
|
Current U.S.
Class: |
424/423 ;
424/400; 424/93.7; 435/325 |
Current CPC
Class: |
C12N 2500/02 20130101;
A61K 35/50 20130101; A61P 17/00 20180101; A61K 38/1841 20130101;
C12N 5/0605 20130101; A01N 1/0221 20130101; C12N 2502/025 20130101;
A61K 38/39 20130101; A61P 43/00 20180101; A61K 35/28 20130101; A61K
38/57 20130101; A61P 17/02 20180101; C12N 2501/115 20130101; A61K
38/1825 20130101 |
Class at
Publication: |
424/423 ;
435/325; 424/400; 424/93.7 |
International
Class: |
A61M 31/00 20060101
A61M031/00; A61P 43/00 20060101 A61P043/00; A61K 35/50 20060101
A61K035/50; A61P 17/02 20060101 A61P017/02; C12N 5/071 20100101
C12N005/071; A61K 9/00 20060101 A61K009/00 |
Claims
1. A placental product comprising: a amniotic membrane, wherein the
amniotic membrane: a. comprises viable therapeutic cells; and b. is
substantially free of functional CD14+ macrophages; and optionally,
wherein the viable therapeutic cells are native to the amniotic
membrane.
2. The placental product of claim 1, wherein the amniotic membrane
is substantially free of vascularized tissue or vascularized
tissue-derived immunogenic cells.
3. The placental product of claim 1, wherein the amniotic membrane
comprises a layer of epithelial cells.
4. The placental product of claim 1, wherein the amniotic membrane
comprises one, two, or three layers selected from: a compact layer,
a layer of fibroblast, and a spongy layer.
5. The placental product of claim 1, wherein the amniotic membrane
is substantially free of immunogenic maternal cells.
6. The placental product of claim 1, wherein the amniotic membrane
is substantially free of maternal dendritic cells.
7. The placental product of claim 1, wherein the amniotic membrane
is substantially free of maternal leukocytes.
8. The placental product of claim 1, wherein the viable therapeutic
cells comprise one or more of: a. MSCs; b. fibroblasts; c.
epithelial cells; d. stromal cells; and e. stromal cells and
epithelial cells.
9. The placental product of claim 8, wherein the amniotic membrane
is substantially free of vascularized tissue or vascularized
tissue-derived immunogenic cells.
10. The placental product of claim 9, wherein the amniotic membrane
comprises a layer of epithelial cells.
11. The placental product of claim 9, wherein the amniotic membrane
comprises one, two, or three layers selected from: a compact layer,
a layer of fibroblast, and a spongy layer.
12. The placental product of claim 8, wherein the amniotic membrane
is substantially free of immunogenic maternal cells.
13. The placental product of claim 8, wherein the amniotic membrane
is substantially free of maternal dendritic cells.
14. The placental product of claim 8, wherein the amniotic membrane
is substantially free of maternal leukocytes.
15. The placental product of any of claims 8-14, wherein at least:
about 40%, or about 50%, or about 60%, or about 70%, or about
74.3%, or about 83.4 or about 90%, or about 92.5% of the stromal
cells are viable.
16. The placental product of claim 15, wherein the stromal cells
are about 2,000 to about 15,000 in number per cm.sup.2 of the
amniotic membrane.
17. The placental product of any of claims 15, wherein the stromal
cells are at least: about 2,000, or about 2,400, or about 4,000, or
about 6,000, or about 8,000, or about 10,000, or about 10,585, or
about 15,000 in number per cm.sup.2.
18. The placental product of any of claims 8-14, wherein about 40%
to about 92.5% of the stromal cells are viable.
19. The placental product of claim 18, wherein the stromal cells
are about 2,000 to about 15,000 in number per cm.sup.2 of the
amniotic membrane.
20. The placental product of any of claims 19, wherein the stromal
cells are at least: about 2,000, or about 2,400, or about 4,000, or
about 6,000, or about 8,000, or about 10,000, or about 10,585, or
about 15,000 in number per cm.sup.2.
21. The placental product of any of claims 1-14, wherein the
amniotic membrane comprises about 2,000 to about 15,000 stromal
cells per cm.sup.2 of the amniotic membrane, optionally, wherein
the stromal cells are native to the amniotic membrane.
22. The placental product of claim 21, wherein at least: about 40%,
or about 50%, or about 60%, or about 70%, or about 74.3%, or about
83.4 or about 90%, or about 92.5% of the stromal cells are
viable.
23. The placental product of claim 21, wherein about 40% to about
92.5% of the stromal cells are viable.
24. The placental product of any of claims 1-14, wherein the
amniotic membrane comprises at least: about 2,000, or about 2,400,
or about 4,000, or about 6,000, or about 8,000, or about 10,000, or
about 10,585, or about 15,000 stromal cells per cm.sup.2 of the
amniotic membrane, optionally, wherein the stromal cells are native
to the amniotic membrane.
25. The placental product of claim 24, wherein at least: about 40%,
or about 50%, or about 60%, or about 70%, or about 74.3%, or about
83.4 or about 90%, or about 92.5% of the stromal cells are
viable.
26. The placental product of claim 24, wherein about 40% to about
92.5% of the stromal cells are viable.
27. The placental product of any claims 1-14, wherein the amniotic
membrane comprises about fibroblasts in about 10% to about 30%
fibroblasts per total cells.
28. The placental product of any of claims 1-14, wherein the
amniotic membrane comprises fibroblasts in about 2% to about 30%
fibroblasts per total cells.
29. The placental product of any of claims 1-28, wherein the
placental product or amniotic membrane secretes between about 0 to
about 420 pg/mL TNF-.alpha. into a tissue culture medium upon
placing a 2 cm.times.2 cm piece of the placental product in a
tissue culture medium and exposing the tissue product to a
bacterial lipopolysaccharide for about 20 to about 24 hours.
30. The placental product of claim 29, wherein said about between
about 0 to about 420 pg/mL TNF-.alpha. is: about 0 to about 350
pg/mL TNF-.alpha. or 0 to about 280 pg/mL TNF-.alpha..
31. The placental product of any of claims 1-14, wherein the
amniotic membrane further comprises one or more native factors
consisting of the group of IGFBP1, adiponectin,
.alpha.2-macroglobulin, bFGF, EGF, MMP-9 and TIMP1; wherein natives
factors are present in an amount: i. substantially greater per gram
of amniotic membrane than that of a fresh unprocessed amniotic
membrane; ii. substantially greater per native amniotic membrane
cell than that of a fresh unprocessed amniotic membrane; or iii.
substantially greater per .mu.m of amniotic membrane.
32. The placental product of any of claims 1-14, wherein the
amniotic membrane has a thickness of about 20 .mu.m to about 50
.mu.m.
33. The placental product of any of claims 1-14, wherein the
amniotic membrane comprises a basement membrane.
34. The placental product of any of claims 1-14, further comprising
a chorionic membrane, optionally wherein the chorionic membrane is
substantially free of trophoblasts.
35. A placental product comprising: a cryopreservation medium and
an amniotic membrane, wherein: a. the amniotic membrane is
substantially free of functional CD14+ macrophages; and b. the
cryopreservation medium comprises a cryopreserving amount of a
cryopreservative; and optionally, wherein the amniotic membrane is
substantially free of vascularized tissue or vascularized
tissue-derived immunogenic cells.
36. The placental product of claim 35, wherein the amniotic
membrane comprises viable therapeutic cells, optionally, wherein
the viable therapeutic cells are native to the amniotic membrane
and of one or more of the types: a. MSCs; b. fibroblasts; c.
epithelial cells; d. stromal cells and e. stromal cells and
epithelial cells.
37. The placental product of claim 36, wherein the cryopreservative
comprises a cell-permeating cryopreservative, a non-cell-permeating
cryopreservative, or a combination thereof, optionally wherein the
permeating cryopreservative comprises: a. DMSO; or b. DMSO in a
majority amount.
38. The placental product of claim 37, wherein the cell-permeating
cryopreservative: a. does not comprise glycerol in a majority
amount; or b. does not comprises a substantial amount of
glycerol.
39. The placental product of claim 37, wherein the cell-permeating
cryopreservative comprises a DMSO in amount of: about 2% to about
20%, about 5% to about 20%, about 5% to about 15%, or about 7% to
about 13%.
40. The placental product of claim 37, wherein the cryopreservation
medium is present in an amount of at least: about 20 ml, about 30
ml, about 35 ml, about 40 ml, about 45 ml, or about 50 ml.
41. The placental product of claim 39, wherein the cryopreservation
medium is present in an amount of at least: about 20 ml, about 30
ml, about 35 ml, about 40 ml, about 45 ml, or about 50 ml.
42. The placental product of claim 37, wherein the cryopreservation
medium further comprises albumin, optionally wherein the albumin is
HSA.
43. The placental product of claim 39, wherein the cryopreservation
medium further comprises albumin, optionally wherein the albumin is
HSA.
44. The placental product of any of claims 36-43, wherein the
cryopreservative comprises a non-cell-permeating cryopreservative
selected from is a polyvinylpyrrolidone, a starch, a hydroxyethyl
starch, a polysacharide, a monosaccharides, a sugar alcohol, an
alginate, a trehalose, a raffinose, a dextran, or a combination
thereof.
45. The placental product of any of claims 36-43, wherein at least:
about 40%, or about 50%, or about 60%, or about 70%, or about
74.3%, or about 83.4 or about 90%, or about 92.5% of the stromal
cells are viable after a freeze-thaw cycle.
46. The placental product of claim 45, wherein the stromal cells
are about 2,000 to about 15,000 in number per cm.sup.2 of the
amniotic membrane.
47. The placental product of claim 45, wherein the stromal cells
are at least: about 2,000, or about 2,400, or about 4,000, or about
6,000, or about 8,000, or about 10,000, or about 10,585, or about
15,000 in number per cm.sup.2.
48. The placental product of any of claims 36-43, wherein about 40%
to about 92.5% of the stromal cells are viable after a freeze-thaw
cycle.
49. The placental product of claim 48, wherein the stromal cells
are about 2,000 to about 15,000 in number per cm.sup.2 of the
amniotic membrane.
50. The placental product of any of claims 48, wherein the stromal
cells are at least: about 2,000, or about 2,400, or about 4,000, or
about 6,000, or about 8,000, or about 10,000, or about 10,585, or
about 15,000 in number per cm.sup.2.
51. The placental product of any of claims 35-43, wherein the
amniotic membrane comprises about 5,000 to about 50,000 stromal
cells per cm.sup.2 of the amniotic membrane, optionally, wherein
the stromal cells are native to the amniotic membrane.
52. The placental product of claim 51, wherein at least: about 40%,
or about 50%, or about 60%, or about 70%, or about 74.3%, or about
83.4 or about 90%, or about 92.5% of the stromal cells are viable
after a freeze-thaw cycle.
53. The placental product of claim 51, wherein about 40% to about
92.5% of the stromal cells are viable.
54. The placental product of any of claims 35-43, wherein the
amniotic membrane comprises at least: about 2,000, or about 2,400,
or about 4,000, or about 6,000, or about 8,000, or about 10,000, or
about 10,585, or about 15,000 stromal cells per cm.sup.2 of the
amniotic membrane, optionally, wherein the stromal cells are native
to the amniotic membrane.
55. The placental product of claim 54, wherein at least: about 40%,
or about 50%, or about 60%, or about 70%, or about 74.3%, or about
83.4 or about 90%, or about 92.5% of the stromal cells are viable
after a freeze-thaw cycle.
56. The placental product of claim 54, wherein about 40% to about
92.5% of the stromal cells are viable after a freeze-thaw
cycle.
57. The placental product of any claims 35-43, wherein the amniotic
membrane comprises fibroblasts in about 2% to about 30% fibroblasts
per total cells.
58. The placental product of any of claims 35-43, wherein the
amniotic membrane comprises CD14+ macrophage at less than about 10%
or less than about 2% or less than about 0.5% of the total
cells.
59. The placental product of any of claims 35-43, wherein the
amniotic membrane is substantially free of: a. maternal dendritic
cells, maternal leukocytes, or a combination thereof, or b.
immunogenic maternal cells,
60. The placental product of any of claims 35-43, wherein the
product comprises about 2,000 to about 15,000 stromal cells per
cm.sup.2 and wherein the viability of said stromal cells after a
freeze-thaw cycle is about 70% to about 95% relative to fresh
placental or amniotic membrane.
61. The placental product of any of claims 35-43, wherein after a
freeze-thaw cycle, the placental product or amniotic membrane
secretes between about 0 to about 420 pg/mL TNF-.alpha. into a
tissue culture medium upon placing a 2 cm.times.2 cm piece of the
placental product in a tissue culture medium and exposing the
tissue product to a bacterial lipopolysaccharide for about 20 to
about 24 hours.
62. The placental product of any of claims 35-43, wherein after a
refrigeration-freeze-thaw cycle, the placental product or amniotic
membrane secretes between about 0 to about 420 pg/mL TNF-.alpha.
into a tissue culture medium upon placing a 2 cm.times.2 cm piece
of the placental product in a tissue culture medium and exposing
the tissue product to a bacterial lipopolysaccharide for about 20
to about 24 hours.
63. The placental product of claim 61, wherein said about between
about 0 to about 420 pg/mL TNF-.alpha. is: about 0 to about 350
pg/mL TNF-.alpha. or 0 to about 280 pg/mL TNF-.alpha..
64. The placental product of any of claims 35-43, wherein the
amniotic membrane further comprises one or more native factors
selected from the group consisting of IGFBP1, adiponectin,
.alpha.2-macroglobulin, bFGF, EGF, MMP-9 and TIMP1; wherein the one
or more native factors are present in an amount, wherein the amount
is: i. substantially greater per gram of amniotic membrane than
that of a fresh unprocessed amniotic membrane; ii. substantially
greater per native amniotic membrane cell than that of a fresh
unprocessed amniotic membrane; or iii. substantially greater per
.mu.m of amniotic membrane.
65. The placental product of any of claims 35-43, wherein the
amniotic membrane has a thickness of about 20 .mu.m to about 50
.mu.m.
66. The placental product of any of claims 35-43, further
comprising a chorionic membrane, optionally wherein the chorionic
membrane is substantially free of trophoblasts.
67. The placental product of claim 66, wherein the amniotic
membrane and the chorion membrane are associated to each another in
the native architecture.
68. The placental product of claim 66, wherein the amniotic
membrane and the chorionic membrane are not attached to one another
in the native architecture.
69. The placental product of any of claims 35-43, wherein the
amniotic membrane comprises a layer of epithelial cells.
70. The placental product of any of claims 35-43, wherein the
amniotic membrane comprises one, two, or three layers selected
from: a compact layer, a layer of fibroblast, and a spongy
layer.
71. The placental product of any of claims 35-43, wherein the
amniotic membrane has a thickness of about 20 .mu.m to about 50
.mu.m.
72. The placental product of any of claims 35-43, wherein the
amniotic membrane comprises a layer of epithelial cells.
73. The placental product of any of claims 35-43, wherein the
amniotic membrane comprises a basement membrane.
74. A placental product comprising: a cryopreservation medium and
an amniotic membrane, wherein: a. the amniotic membrane: i.
comprises a compact layer, layer of fibroblast, and a spongy layer,
wherein each of said layers comprises viable therapeutic cells; and
ii. is substantially free of vascularaized tissue and functional
CD14+ macrophages; and b. the cryopreservation medium comprises a
cryopreserving amount of a cryopreservative.
75. The placental product of claim 74, wherein the amniotic
membrane comprises about 2,000 to about 15,000 stromal cells per
cm.sup.2 of the amniotic membrane.
76. The placental product of claim 75, wherein at least: about 40%,
or about 50%, or about 60%, or about 70%, or about 74.3%, or about
83.4 or about 90%, or about 92.5% of the stromal cells are
viable.
77. The placental product of any claim 75, wherein about 40% to
about 92.5% of the stromal cells are viable.
78. The placental product of claim 74, wherein the amniotic
membrane comprises at least: about 2,000, or about 2,400, or about
4,000, or about 6,000, or about 8,000, or about 10,000, or about
10,585, or about 15,000 stromal cells per cm.sup.2 of the amniotic
membrane.
79. The placental product of claim 75, wherein at least: about 40%,
or about 50%, or about 60%, or about 70%, or about 74.3%, or about
83.4 or about 90%, or about 92.5% of the stromal cells are viable
after a freeze-thaw cycle.
80. The placental product of claim 75, wherein about 40% to about
92.5% of the stromal cells are viable after a freeze-thaw
cycle.
81. The placental product of any of claims 74-80, wherein the
amniotic membrane further comprises a basement membrane.
82. The placental product of any of claims 74-81, wherein the
amniotic membrane has a thickness of about 20 .mu.m to about 50
.mu.m.
83. The placental product of any of claims 74-82, wherein the
cryopreservative comprises DMSO.
84. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises MSCs in an amount of: at
least about 1%, at least about 2%, at least about 3%, at least
about 4%, at least about 5%, about 1% to about 10%, or about 3% to
about 10%, relative to the total number of cells in the amniotic
membrane.
85. The placental product of claim 84, wherein at least about 40%,
about 50%, about 60%, or about 70% of the MSCs are viable.
86. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises fibroblasts in an amount
of: about 1%, about 20%, about 5% to about 15%, at least about 1%,
at least about 2%, at least about 3%, or at least about 4 relative
to the total number of cells in the amniotic membrane.
87. The placental product of claim 86, wherein at least: about 40%,
about 50%, about 60%, or about 70% of the fibroblasts are
viable.
88. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises stromal cells in an amount
of: about 5% to about 40%, about 5% to about 30%, about 10% to
about 30%, about 15% to about 25%, at least about 5%, at least
about 10%, or at least about 15%, relative to the total number of
cells in the amniotic membrane.
89. The placental product of claim 88, wherein at least: about 40%,
about 50%, about 60%, or about 70% of the stromal cells are viable
after a freeze-thaw cycle
90. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises epithelial cells in an
amount of: about 60% to about 90%, about 70% to about 90%, about
40% to about 90%, about 50% to about 90%, at least about 40%, at
least about 50%, least about 60%, or at least about 70%, relative
to the total number of cells in the amniotic membrane.
91. The placental product of claim 90, wherein at least: about 40%,
about 50%, about 60%, or about 70% of the epithelial cells are
viable after a freeze-thaw cycle.
92. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises MSCs and functional
macrophages in a ratio of greater than about any of: 5:1, 7:1, or
10:1.
93. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises fibroblasts and functional
macrophages in a ratio of greater than about any of: 10:1, 15:1,
20:1, or 25:1.
94. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises fibroblasts and MSCs in a
ratio of: about 4:1 to about 1:1 or about 3:1 to about 3:2, or
about 2:1.
95. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises MSCs in an amount of: at
least about 1,000 cells/cm.sup.2' at least about 2,000
cells/cm.sup.2, about 1,000 to about 5,000 cells/cm.sup.2, or about
2,000 to about 5,000 cells/cm.sup.2.
96. The placental product of claim 95, wherein at least: about 40%,
about 50%, about 60%, or about 70% of the MSCs are viable after a
freeze-thaw cycle
97. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises fibroblasts in an amount
of: at least about 2,000 cells/cm.sup.2, at least about 4,000
cells/cm.sup.2, about 2,000 to about 9,000 cells/cm.sup.2 , or
about 2,000 to about 9,000 cells/cm.sup.2.
98. The placental product of claim 97, wherein at least: about 40%,
about 50%, about 60%, or about 70% of the fibroblasts are viable
after a freeze-thaw cycle
99. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises stromal cells in an amount
of: at least about 4,000, at least about 8,000 cells/cm.sup.2,
about 4,000 to about 18,000 cells/cm.sup.2, or about 4,000 to about
18,000 cells/cm.sup.2.
100. The placental product of claim 99, wherein at least: about
40%, about 50%, about 60%, or about 70% of the stromal cells are
viable after a freeze-thaw cycle.
101. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises epithelial cells in an
amount of: at least about 10,000 cells/cm.sup.2, at least about
20,000 cells/cm.sup.2, at least about 32,000 cells/cm.sup.2, about
10,000 to about 72,000 cells/cm.sup.2 , about 20,000 to about
72,000 cells/cm.sup.2, or about 32,000 to about 72,000
cells/cm.sup.2
102. The placental product of claim 101, wherein at least: about
40%, about 50%, about 60%, or about 70% of the epithelial cells are
viable after a freeze-thaw cycle.
103. The placental product of any of claims 1-14, 35-43, or 74-80,
wherein the amniotic membrane comprises functional macrophages in
an amount of: less than about 3,000 cells/cm.sup.2, less than about
1,000 cells/cm.sup.2, or less than about 500 cells/cm.sup.2.
104. A method of treating a wound of a subject comprising
administering the placental product of any of the preceding Claims
to the wound.
105. The method of claim 94, wherein the wound is an ulcer.
106. The method of claim 95, wherein the ulcer is a foot ulcer,
optionally a diabetic foot ulcer.
107. The method of claim 95, wherein the ulcer is a diabetic foot
ulcer.
108. The method of any of claims 93-97, wherein the subject has
diabetes.
109. A method of ligament or tendon surgery comprising applying the
placental product of any of claims 1-103 to a ligament or
tendon.
110. The method of claim 109, wherein the ligament or tendon
surgery is a grafting surgery, a reconstruction surgery, or a
repair of a torn ligament or tendon.
111. The method of claim 110, wherein the grafting surgery
comprises the attachment of a graft to a biological substrate,
optionally, wherein the biological substrate is bone.
112. The method of claim 111, wherein the graft is an allograft, a
xenograft, or an autologous graft.
113. The method of claim 110, wherein the ligament or tendon
surgery is selected from: knee surgery, shoulder surgery, leg
surgery, and arm surgery, elbow surgery, finger surgery, hand
surgery, wrist surgery, toe surgery, foot surgery, ankle
surgery.
114. The method of claim 110, wherein the tendon is hamstring
tendon, a bicep tendon, an Achilles Tendon, an extensor tendon, or
a rotator cuff tendon.
115. The method of claim 110, wherein the step of applying the
placental product comprises: suturing the placental product to the
tendon or ligament, enveloping the tendon or ligament with the
placental product, or a combination thereof.
116. A method of tissue grafting comprising applying the placental
product of any of claims 1-103 to a tissue graft, and attaching the
tissue graft to a biological substrate.
117. The method of claim 116, wherein the placental product is
applied to a portion of the tissue graft which is attached to the
biological substrate.
118. The method of claim 117, wherein the step of applying the
placental product comprises: suturing the placental product to the
graft, enveloping graft with the placental product, or a
combination thereof.
119. The method of claim 118, wherein the tissue graft comprises a
tissue selected from: skin, cartilage, ligament, tendon,
periosteum, perichondrium, synovium, fascia, and mesenter.
120. A method of inhibiting fibrosis or adhesion at a wound site
comprising applying the placental product of any of claims 1-103 to
the wound site.
121. The method of claim 120, wherein the wound site is surgery
induced or associated with surgery.
122. The method of claim 121 wherein the surgery is a surgery
selected from: spine, laminectomy, knee, shoulder, or child birth,
eye, cardiovascular, angiogenesis stimulation, burn, and
brain/neurological procedures.
123. The method of claim 120, wherein the wound site is a trauma
related wound.
124. A method of treating a tissue injury of a subject comprising
administering the placental product of any of claims 1-103 to the
tissue injury.
125. The method of claim 124, wherein the tissue injury is an
ulcer.
126. The method of claim 125, wherein the ulcer is a foot ulcer,
optionally a diabetic foot ulcer.
127. The method of claim 126, wherein the ulcer is a diabetic foot
ulcer.
128. The method of any of claims 125 wherein the subject has
diabetes.
129. The method of any of claims 125 wherein the wound is
associated with ischemia.
130. A method of promoting migration or proliferation of at least
one cell selected from the group consisting of fibroblasts,
epithelial cells, and endothelial cells] in a subject comprising
administering the placental product of any of claims 1-103 a
subject in need thereof.
131. A method of reorganizing extracellular matrix of a subject
comprising administering the placental product of any of claims
1-103 to the subject.
132. A method of treating a wound comprising providing at least one
factor that is a chemotactic factor or a growth factor to the wound
by administering the placental product of any of claims 1-103 to
the subject.
133. A method of providing stem cells to tissue of a subject
comprising administering the placental product of any of claims
1-103 to the subject.
Description
RELATED APPLICATIONS
[0001] This application claims priority to:
[0002] U.S. Provisional Applications Ser. No, 61/338,464 entitled
"Selectively Immunodepleted Chorionic Membranes" , filed on Feb.
18, 2010 bearing Docket No. 22924US01,
[0003] U.S. Provisional Applications Ser. No, 61/338,489 entitled
"Selectively Immunodepleted Amniotic Membranes", filed on Feb. 18,
2010 bearing Docket No. 22925US01, and
[0004] U.S. Provisional Applications Ser. No, 61/369,562 entitled
"Therapeutic Products Comprising Vitalized Placental Dispersions
filed on Jul. 30, 2010 bearing Docket No 23498US01, the contents of
which are hereby incorporated by reference in their entireties.
[0005] This application is being co-filed on Feb. 18, 2011 with,
and incorporates by reference, applications entitled:
[0006] "Methods of Manufacture of Immunocompatible Chorionic
Membrane Products",
[0007] "Immunocompatible Chorionic Membrane Products",
[0008] "Immunocompatible Amniotic Membrane Products",
[0009] "Methods of Manufacture of Immunocompatible Amniotic
Membrane Products",
[0010] "Therapeutic Products Comprising Vitalized Placental
Dispersions" , and
[0011] "Methods of Manufacture of Therapeutic Products Comprising
Vitalized Placental Dispersions"
FIELD OF THE INVENTION
[0012] The present technology relates to products to facilitate
wound healing such as placenta membrane-derived products and
biologic skin. The present technology relates to products to
protect injured or damaged tissue, or as a covering to prevent
adhesions, to exclude bacteria, to inhibit bacterial activity, or
to promote healing or growth of tissue. An example of such a
placental membrane is an amniotic membrane. The field also relates
to methods of manufacturing and methods of use of such
membrane-derived products.
BACKGROUND OF THE INVENTION
[0013] Fresh or decellularized placental membranes have been used
topically in surgical applications since at least 1910 when Johns
Hopkins Hospital reported the use of placental membrane for dermal
applications. Subsequently unseparated amnion and chorion were used
as skin substitutes to treat burned or ulcerated surfaces. During
the 1950's and 60's Troensegaard-Hansen applied boiled amniotic
membranes to chronic leg ulcers.
[0014] The human amniotic membrane (AM) is the innermost of the
fetal membranes deriving from the amniotic sac and constituting the
lining of the amniotic cavity. It is approximately 0.02 to 0.5 mm
thick. The AM consists of five layers: a thin layer rests on the
basement membrane and contacts the amniotic fluid, an underlying
layer of connective tissue attaching the basement membrane that
consists of three layers: a compact layer, a layer of fibroblast,
and a spongy layer. The spongy layer is adjacent to the cellular
layer of the chorion. The amnion is essentially devoid of
vasculature.
[0015] Both fresh and frozen AMs have been used for wound healing
therapy. When fresh AM is used, there is increased risk of disease
transmission. According to published reports, fresh amniotic tissue
exhibits cell viability of 100%, however within 28 days of storage
above 0.degree. C. diminished cell viability to 15 to 35%. Freezing
over a time of 3 weeks reduced cell viability to 13 to 18%,
regardless of the temperature or medium.
[0016] Lee and Tseng report the successful cryopreservation of AM
in glycerol and Dulbeccos Modified Eagle medium (DMEM) at
-80.degree. C., although such cryopreservation dramatically
decreases cell viability. The cryopreservation of AM in glycerol
and DMEM is recommended by the FDA. According to published reports,
glycerol storage of AM resulted in immediate cell death. Glycerol
cryopreserved AM (-80.degree. C.) and glycerol-preserved AM
(-4.degree. C.) are sufficient to provide a matrix for wound
healing, but fail to provide sufficient cell viability to bestow
biological effectiveness
[0017] Gajiwala and Gajiwala report the successful preservation of
AM by freeze-drying (lyophilisation) and gamma-irradiation.
According to this method, AM is pasteurized at 60.degree. C.,
treated with 70% ethanol, and freeze-dried to remove most of the
remaining moisture. Then the AM is sterilized by exposure of 25 kGy
gamma-radiation in a Cobalt 60 Gamma chamber unit or at an
ISO-certified radiation plant. The sterilized AM can be stored at
room temperature for a short period (up to 6 months).
[0018] Gomes reports preservation of AM with lyophilisation
followed by sterilization in ethylene oxide.
[0019] Rama et al reported the cryopreservation of AM in 10%
dimethyl sulfoxide (DMSO) instead of glycerol and achieved a cell
viability of about 40%.
[0020] Two placental tissue graft products containing living cells,
Apligraf and Dermagraft, are currently commercially available. Both
Apligraf and Dermagraft comprise ex vivo cultured cells. Neither
Apligraf nor Dermagraft comprise stem cells. Furthermore, neither
Apligraf nor Dermagraft comprise Insulin-like Growth Factor Binding
Protein-1 (IGFBP-1) and adiponectin, which are key factors in the
natural wound healing process. In addition, neither Apligraf nor
Dermagraft exhibit a protease-to-protease inhibitor ratio favorable
for wound healing. As wound healing is a multi-factorial biological
process, many factors are needed to properly treat a wound;
products having non-native cellular populations are less capable of
healing wounds relative to a product having an optimal population
of cells representing the native array. It would represent an
advance in the art to provide a chorion-derived biologic skin
substitute comprising a population of cells representing the native
array of factors, including, for example, growth factors and
cytokines.
[0021] Apligraf is a living, bi-layered skin substitute
manufactured using neonatal foreskin keratinocytes and fibroblasts
with bovine Type I collagen. As used in this application, Apligraf
refers to the product available for commercial sale in November
2009.
[0022] Dermagraft is cryopreserved human fibroblasts derived from
newborn foreskin tissue seeded on extracellular matrix. According
to its product literature, Dermagraft requires three washing steps
before use which limits the practical implementation of Dermagraft
as a wound dressing relative to products that require less than
three washing steps. As used in this application, Dermagraft refers
to the product available for commercial sale in November 2009.
[0023] Engineered wound dressings such as Apligraf and Dermagraft
do not provide the best potential for wound healing because they
comprise sub-optimal cellular compositions and therefore do not
provide proper wound healing. For example, neither Apligraf nor
Dermagraft comprises stem cells and, as a result, the ratio between
different factors secreted by cells does not enable efficient wound
healing. Additionally, some factors that are important for wound
healing, including EGF, IGFBP1, and adiponectin, are absent from
both Apligraf and Dermagraft. Additionally, some factors, including
MMPs and TIMPs, are present in proportions that differ greatly from
the proportions found in the natural wound healing process; this
difference significantly alters, among other things, upstream
inflammatory cytokine pathways which in turn allows for sub-optimal
micro-environments at the wound site.
[0024] Paquet-Fifield et al. report that mesenchymal stem cells and
fibroblasts are important for wound healing (J Clin Invest, 2009,
119: 2795). No product has yet been described that comprise
mesenchymal stem cells and fibroblasts.
[0025] Both MMPs and TIMPs are among the factors that are important
for wound healing. However, expression of these proteins must be
highly regulated and coordinated. Excess of MMPs versus TIMPs is a
marker of poor chronic wound healing (Liu et al, Diabetes Care,
2009, 32: 117; Mwaura et al, Eur J Vasc Endovasc Surg, 2006, 31:
306; Trengove et al, Wound Rep Reg, 1999, 7: 442; Vaalamo et al,
Hum Pathol, 1999, 30: 795).
[0026] .alpha.2-macroglobulin is known as a plasma protein that
inactivates proteinases from all 4 mechanistic classes: serine
proteinases, cysteine proteinases, aspartic proteinases, and
metalloproteinases (Borth et al., FASEB J, 1992,6: 3345; Baker et
al., J Cell Sci, 2002, 115:3719). Another important function of
this protein is to serve as a reservoir for cytokines and growth
factors, examples of which include TGF, PDGF, and FGF (Asplin et
al, Blood, 2001, 97: 3450; Huang et al, J Biol Chem, 1988; 263:
1535). In chronic wounds like diabetic ulcers or venous ulcers, the
presence of high amount of proteases leads to rapid degradation of
growth factors and delays in wound healing. Thus, a placental
membrane wound dressing comprising .alpha.2-macroglobulin would
constitute an advance in the art.
[0027] An in vitro cell migration assay is important for assessing
the wound healing potential of a skin substitute. The process of
wound healing is highly complex and involves a series of structured
events controlled by growth factors (Goldman, Adv Skin Wound Care,
2004, 1:24). These events include increased vascularization,
infiltration by inflammatory immune cells, and increases in cell
proliferation. The beginning stages of wound healing revolve around
the ability of individual cells to polarize towards the wound and
migrate into the wounded area in order to close the wound area and
rebuild the surrounding tissue. An assay capable of evaluating the
wound healing potential of skin substitutes by examining the
correlation between cell migration and wound healing would
represent an advance in the art.
SUMMARY OF THE INVENTION
[0028] The present invention provides a pharmaceutically acceptable
placental product.
[0029] A placental product according to the present invention
comprises an immunocompatible amniotic membrane in a
cryopreservation medium (optionally cryopreserved) and viable
native therapeutic cells and native therapeutic factors.
[0030] In some embodiments, the amniotic membrane of the placental
product is selectively devitalized.
[0031] There is now provided a placental product that is
selectively depleted of substantially all immunogenic cells.
[0032] There is now provided a placental product that does not
contain ex vivo cultured cells.
[0033] In some embodiments, the placental product further comprises
a chorionic membrane that is selectively devitalized.
[0034] There is now provided a placental product that comprises at
least one of Epidermal Growth Factor, IGFBP1, and Adiponectin.
[0035] Optionally, the therapeutic factors include one or more of
IGFBP1, adiponectin, .alpha.2-macroglobulin, bFGF, and EGF.
Optionally, the therapeutic factors include MMP-9 and TIMP1,
wherein the ratio of MMP-9:TIMP1 is from about 7 to about 10.
Optionally, the therapeutic factors include IGFBP1, adiponectin,
.alpha.2-macroglobulin, bFGF, EGF, MMP-9, and TIMP1. Optionally,
the therapeutic factors include IGFBP1, adiponectin,
.alpha.2-macroglobulin, bFGF, MMP-9, and TIMP1, wherein the the
ratio of MMP-9:TIMP1 is from about 7 to about 10 to one.
Optionally, the therapeutic factor is present in a substantial
amount in comparison to unprocessed human placental membrane.
Optionally, each placental product embodiment optionally is devoid
of ex-vivo expanded cultured cells.
[0036] The present invention also provides a method of
manufacturing a placental product comprising: obtaining a placenta,
wherein the placenta comprises an amniotic membrane, selectively
depleted of immunogenicity, and cryopreserving the placenta,
thereby providing a placental product. According to the present
invention, the step of selective depletion comprises removing
immunogenic cells (e.g. CD14+ macrophages and vascularized
tissue-derived cells) and/or immunogenic factors (e.g. TNF.alpha.).
Optionally, the step of selective depletion comprises removing
CD14+ macrophages by refrigerating the placental product for a
period of time (e.g. about 30-60 mins.) at a temperature above
freezing (e.g. at 2-8.degree. C.), and then freezing, whereby CD14+
macrophages are selectively killed relative to therapeutic
cells.
[0037] The present invention also provides a method of screening a
placental product for therapy comprising assaying the placental
product for immunogenicity and/or therapeutic value. Optionally,
the step of assaying the placental product for immunogenicity
comprises a Mixed Lymphocyte Reaction (MLR) and/or
Lipopolysaccharide (LPS)-induced Tumor Necrosis Factor
(TNF)-.alpha. secretion. Optionally, the step of assaying the
placental product for therapeutic value comprises assaying the
placental product for cell migration induction.
[0038] The present invention also provides a method of treating a
subject comprising administering a placental product to the
subject. Optionally, the step of administering comprises applying
the placental product to a wound, for example, topically applying
the placental product to a skin wound. In one embodiment, a
placental product is used in a tendon or ligament surgery to
promote healing of a tendon or ligament.
[0039] The present inventors have identified a need for the
development of amniotic membrane products comprising at least one
of IGFBP1, and adiponectin, providing superior wound healing
properties.
BRIEF DESCRIPTION OF THE DRAWINGS
[0040] FIG. 1 depicts freezing rates of various freezing
methods.
[0041] FIG. 2 depicts process cell recovery for amniotic membrane
as a function of cryo volume.
[0042] FIG. 3 depicts process cell recovery for chorionic membrane
as a function of cryo volume.
[0043] FIG. 4 depicts the effects of refrigeration time and
freezing parameters on process (cryopreservation) cell recovery for
the amniotic membrane.
[0044] FIG. 5 depicts the effects of refrigeration time and
freezing parameters on process (cryopreservation) cell recovery for
the chorionic membrane.
[0045] FIG. 6 shows representative images of the live/dead staining
of the epithelial layer of fresh amniotic membrane.
[0046] FIG. 7 depicts expression of IL-2sR from T-cells stimulated
by placental derived cells from various membrane preparations.
[0047] FIG. 8 depicts expression of IL-2sR from T-cells stimulated
by placental derived cells from various membrane preparations after
cryopreservation.
[0048] FIG. 9 depicts LPS stimulated TNF a released from various
membrane preparations.
[0049] FIG. 10 shows images of cultured cells isolated from various
membrane preparations.
[0050] FIG. 11 depicts a correlation between IL-2sR release in an
MLR assay of various membrane preparations and the number of CD45+
cells.
[0051] FIG. 12 depicts the IL-2sR release in an MLR assay of
amniotic membrane preparations and the number of CD45+ cells.
[0052] FIG. 13 depicts expression of EGF (A), IGFBP1 (B), and
Adiponectin (C) in amniotic and/or chorionic membranes.
[0053] FIG. 14 depicts expression of IFN-2.alpha. and TGF-.beta.3
in amniotic membrane homogenates.
[0054] FIG. 15 depicts expression of BMP-2, BMP-4, PLAB, PIGF (A),
and IGF-1 (B) in amniotic membrane homogenates.
[0055] FIG. 16 depicts the ratio of MMPs to TIMPs in various
membrane products.
[0056] FIG. 17 depicts expression of EGF in chorion and amnion
membranes measured by ELISA in two separate placenta donors.
[0057] FIG. 18 depicts the Cell Biolabs 24-well Cytoselect wound
healing assay.
[0058] FIG. 19 depicts representative images of HMVECs treated with
5% conditioned media from amniotic, chorionic, or a combination of
amniotic/chorionic preparations.
[0059] FIG. 20 depicts the remarkable efficacy of placental
products for treating diabetic foot ulcers in patient 1.
[0060] FIG. 21 depicts the remarkable efficacy of placental
products for treating diabetic foot ulcers in patient 2.
DETAILED DESCRIPTION OF THE INVENTION
[0061] As used herein, the following definitions apply:
[0062] "Examplary" (or "e.g." or "by example") means a non-limiting
example.
[0063] "hCMSCs: means human chorionic membrane stromal cells .
hCMSCs are generally positive for CD73?, CD70, CD90, CD105, and
CD166; negative for CD45 and CD34,. hCMSCs differentiate to
mesodermal lineages (osteogenic, chondrogenic, and adipogenic).
[0064] "Selective depletion of immunogenicity" or "selective
depletion of immunogenic cells or factors" or "selective depletion"
means a placental product that retains live therapeutic cells
and/or retains therapeutic efficacy for the treatment of tissue
injury yet is free, substantially free, or depleted of at least one
of immune cell type (e.g. CD14+ macrophages, trophoblasts, and/or
vascular-tissue derived cells) and/or immunogenic factor that are
otherwise present in a native placenta or amniotic membrane.
[0065] "MSC" means mesenchymal stem cells and include fetal,
neonatal, adult, or post-natal. "MSCs" include amniotic MSCs
(AMSCs). MSCs generally express one or more of CD73, CD90, CD105,
and CD166.
[0066] "Native cells" means cells that are native, resident, or
endogenous to the placental membrane, i.e. cells that are not
exogenously added to the placental membrane.
[0067] "Native factors" means placental membrane factors that are
native, resident, or endogenous to the placental membrane, i.e.
factors that are not exogenously added to the placental
membrane.
[0068] "Placental products" means the instant placental products
disclosed and claimed herein.
[0069] "Substantial amount" of an element of the present invention,
e.g. native factors, native cells, therapeutic factors, or
selective depletion, means a value at least about 10% or more in
comparison to an unprocessed, not cryopreserved, fresh membrane
sample. A substantial amount can optionally be at least about
50%.
[0070] "Therapeutic cells" or "beneficial cells" means stromal
cells, MSCs, fibroblasts, and/or epithelial cells.
[0071] "Therapeutic factors" means placenta- or amniotic membrane-
derived factors that promote wound healing. Examples include
IGFBP1, adiponectin, .alpha.2-macroglobulin, and/or bFGF. Other
examples include MMP-9 and TIMP1.
[0072] "Stromal cells" refers to a mixed population of cells
present (optionally in native proportions) composed of neonatal
mesenchymal stem cells and neonatal fibroblasts. Both neonatal
mesenchymal stem cells and neonatal fibroblasts are
immunoprivileged; neither express surface proteins present on
immunogenic cell types.
[0073] In some embodiments, the present technology discloses
placental products for clinical use, including use in wound healing
such as diabetic foot ulcers, venous leg ulcers, and burns. The
manufacturing process optionally eliminates essentially all
potentially immunogenic cells from the placental membrane while
preserving of specific cells that play an important role in wound
healing.
[0074] In some embodiments, the present technology discloses a
placental product that is selectively devitalized. There is now
provided a placental product that is selectively depleted of
substantially all immunogenic cells. There is now provided a
placental product that does not contain ex vivo cultured cells.
There is now provided a placental product that comprises at least
one of IGFBP1, and adiponectin. There is now provided a placental
product that comprises Epidermal Growth Factor, IGFBP1. There is
now provided a placental product that comprises adiponectin.
[0075] In some embodiments, the present technology discloses a
method of cyropreserving a placental product that preserves the
viability of specific beneficial cells that are the primary source
of factors for the promotion of healing to the wound healing
process while selectively depleting immunogenic cells (e.g. killing
or rendering non-immunogenic).
[0076] In some embodiments, the present technology discloses a
bioassay to test immunogenicity of manufactured placental
products.
[0077] In some embodiments, the present technology discloses a
placental product exhibiting a therapeutic ratio of MMP to TIMP
comparable to that exhibited in vivo. The present inventors have
identified a need for the development of placental products
exhibiting a ratio of MMP-9 and TIMP1 of about 7-10 to one.
[0078] In some embodiments, the present technology discloses a
placental product that comprises .alpha.2-macroglobulin.
[0079] There is now provided a placental product that inactivates
substantially all serine proteinases, cysteine proteinases,
aspartic proteinases, and metalloproteinases present in the
amniotic membrane. There is now provided a placental product that
inactivates substantially all serine proteinases present in the
amniotic membrane. There is now provided a placental product that
inactivates substantially all cysteine proteinases present in the
amniotic membrane. There is now provided a placental product that
inactivates substantially all aspartic proteinases present in the
amniotic membrane. There is now provided a placental product that
inactivates substantially all metalloproteinases present in the
amniotic membrane.
[0080] In some embodiments, the present technology discloses a
placental product that comprises bFGF.
[0081] In some embodiments, the present technology discloses a
placental product exhibiting a protease-to-protease inhibitor ratio
favorable for wound healing.
[0082] In some embodiments, the present technology discloses a cell
migration assay capable of evaluating the wound-healing potential
of a placental product.
[0083] IGFBP1 and adiponectin are among the factors that are
important for wound healing. Evaluation of proteins derived from
placental products prepared according to the presently disclosed
technology reveal that EGF is one of the major factors secreted in
higher quantities by these tissues. Additionally, the importance of
EGF for wound healing together with high levels of EGF detected in
the presently disclosed amniotic membranes support selection of EGF
as a potency marker for evaluation of membrane products
manufactured for clinical use pursuant to the present
disclosure.
[0084] The present technology discloses a cryopreservation
procedure for a placental product that selectively depletes
immunogenic cells and preserves the viability of other beneficial
cells (including at least one or 2 or all of mesenchymal stem
cells, epithelial cells and fibroblasts . In some embodiments, the
beneficial cells are the primary source of factors for the
promotion of healing.
[0085] Placental products, their usefulness, and their
immunocompatability are surprisingly enhanced by depletion of
maternal trophoblast and selective elimination of CD14+ fetal
macrophages. Immunocompatability can be demonstrated by any means
commonly known by the skilled artisan, such demonstration can be
performed by the mixed Lymphocyte Reaction (MLR) and by
lipopolysaccharide (LPS)-induced Tumor Necrosis Factor
(TNF)-.alpha. secretion.
[0086] The instant placental products contain bFGF optionally at a
substantial concentration.
[0087] The instant placental products optionally secrete factors
that stimulate cell migration and/or wound healing. The presence of
such factors can be demonstrated by any commonly recognized
method,
[0088] For example, commercially available wound healing assays
exist (Cell Biolabs) and cell migration can be assessed by cell
line HMVEC (Lonza Inc.). In one embodiment, conditioned medium from
the present placental products enhance cell migration.
[0089] The placental products disclosed herein are useful in
treating a number of wounds including: tendon repair, cartilage
repair (e.g. femoral condyle, tibial plateau), ACL replacement at
the tunnel/bone interface, dental tissue augmentation, fistulas
(e.g. Crohn's disease, G-tube, tracheoesophogeal), missing tissue
at adhesion barriers (e.g. nasal septum repair, vaginal wall
repair, abdominal wall repair, tumor resection), dermal wounds
(e.g. partial thickness burns, toxic epidermal necrolysis,
epidermolysis bullosa, pyoderma gangrenosum, ulcers e.g. diabetic
ulcers (e.g. foot), venous leg ulcers), surgical wounds, hernia
repair, tendon repair, bladder repair, periosteum replacement,
keloids, organ lacerations, epithelial defects, and repair or
replacement of a tympanic membrane.
[0090] The placental products disclosed herein exhibit one or more
of the following properties beneficial to the wound healing
process: [0091] a. an epithelial cell layer, wherein the
approximate number of cells per cm2 of the amniotic membrane is
about 10,000 to about 360,000 or about 40,000 to about 90,000.
[0092] b. a thick basement membrane (comprising one or more of
Collagen Type I, Ill, IV, laminin, and fibronectin), [0093] c. a
stromal cell layer; [0094] d. an amniotic membrane with a thickness
of about 20 to about 50 .mu.m, [0095] e. high thrombin activity,
[0096] f. low immunogenicity, [0097] g.
cryopreserved/cryopreserveable, [0098] h. amniotic MSC, [0099] i.
analgesic effect [0100] j. reduces scarring, [0101] k.
anti-inflammatory proteins such as IL-1a and IL-10, [0102] l.
anti-inflammatory suppression of lymphocyte reactivity in vitro,
for example by inhibition of CD8+ and CD4+ proliferation or
increased CD4+ Treg cells, [0103] m. antibacterial proteins such as
defensins and allantoin (bacteriolytic proteins), [0104] n.
angiogenic and mitogenic factors that promote re-epithelialization
such as EGF, HGF, and VEGF, [0105] o. cells that are positive for
CD70, CD90, CD105, and CD166 and negative for CD45 and CD34, [0106]
p. cells that express HLA-G, [0107] q. cells that express a
placenta specific MHC-1 antigen important to immune tolerance that
inhibits both NK cytolysis and and T-cell-mediated cytolysis and
activation of immune cells (e.g. interferon-y secretion);, [0108]
r. cells that express IDO and FAS ligand, which likely contribute
to immune tolerance, [0109] s. cells with a capacity to
differentiate into 1-Human Amniotic Epithelial Cells (hAECs) [0110]
t. cells with a capacity to differentiate to neural, hepatocyte,
and pancreatic cells, [0111] u. Human Amniotic Membrane Stromal
Cells (hAMSCs) differentiate to mesodermal lineages (osteogenic,
chondrogenic, and adipogenic) and to all three germ layers-ectoderm
(neural), mesoderm (skeletal muscle, cardiomyocytic, and
endothelial), and ectoderm (pancreatic), [0112] v. Cells that
expression CD49d by hAMSCs distinguishes hAMSCs from hAECs, [0113]
w. hAMSCs that positive for the embryonic cytoplasmic marker Oct-4
that plays a role in maintaining pluripotency and self renewal,
[0114] x. hAECs that are positive for SSEA-3, SSEA-4, TRA-1-60,
TRA-1-81, and negative for SSEA-4 and non-tumorogenic.
[0115] The present inventors have now identified a need for the
development of placental products that do not contain ex vivo
cultured cells.
[0116] The present inventors have now identified a need for the
development of placental products comprising IGFBP1.
[0117] The present inventors have now identified a need for the
development of placental products comprising adiponectin.
[0118] The present inventors have now identified a need for the
development of placental products exhibiting a protease-to-protease
inhibitor ratio favorable for wound healing.
[0119] The present inventors have now identified a need for the
development of a method of cyropreserving placental products that
preserves the viability of specific cells that are other beneficial
cells that are the primary source of factors for the promotion of
healing to the wound healing process while selectively depleting
immunogenic cells from chorionic membranes.
[0120] The present inventors have now identified a need for the
development of a bioassay to test immunogenicity of manufactured
placental products.
[0121] The present inventors have now identified a need for the
development of placental products exhibiting a ratio of MMP to TIMP
comparable to that exhibited in vivo. The present inventors have
now identified a need for the development of placental products
exhibiting a ratio of MMP-9 and TIMP1 of about 7 - 10 to one.
[0122] The present inventors have now identified a need for the
development of placental products that comprise
.alpha.2-macroglobulin.
[0123] The present inventors have now identified a need for the
development of placental products that inactivate serine
proteinases, cysteine proteinases, aspartic proteinases, and
metalloproteinases. The present inventors have now identified a
need for the development of placental products that inactivate
serine proteinases. The present inventors have now identified a
need for the development of placental products that inactivate
cysteine proteinases. The present inventors have now identified a
need for the development of placental products that inactivate
aspartic proteinases. The present inventors have now identified a
need for the development of placental products that inactivate
metalloproteinases.
[0124] The present inventors have now identified a need for the
development of placental products that comprise bFGF.
[0125] The present inventors have now identified a need for the
development of a cell migration assay to evaluate the potential of
placental membrane products.
[0126] The present inventors have now identified a need for the
development of a placental product for wound healing that comprises
mesenchymal stem cells, epithelial cells and fibroblasts.
[0127] Placental Product
[0128] Overview
[0129] One embodiment of the present invention provides a placental
product comprising a cryopreservation medium and an amniotic
membrane, wherein the amniotic membrane comprises viable native
therapeutic cells and native therapeutic factors, and wherein the
cryopreservation medium comprises a cryopreserving amount of a
cryopreservative. According to this embodiment, the amniotic
membrane is substantially free of at least one at least one or both
of the following immunogenic cell types: CD14+ macrophages and
vascularized tissue-derived cells.
[0130] In one embodiment, the amniotic membrane comprises one or
more layers which exhibit the architecture of the native amniotic
membrane (e.g. has not been homogenized or treated with
collagenase).
[0131] In one embodiment, the placental product is suitable for
dermal application to a wound.
[0132] With the teachings provided herein, the skilled artisan can
now produce the present placental products. The present disclosure
provides methods of manufacture that produce the technical features
of the present placental products. Accordingly, in one embodiment,
the placental product is manufactured by steps taught herein. The
present placental products are not limited to products manufactured
by the methods taught here. For example, products of the present
invention could be produced through methods that rely on screening
steps; e.g. steps to screen for preparations with the described
technical features and superior properties.
[0133] The present placental product comprises one or more of the
following technical features: [0134] a. the viable therapeutic
native cells are capable of differentiating into cells of more than
one lineage (e.g. osteogenic, adipogenic and/or chonodrogenic
lineages), [0135] b. the native therapeutic factors include IGFBP1,
[0136] c. the native therapeutic factors include adiponectin,
[0137] d. the native therapeutic factors include
.alpha.2-macroglobulin, [0138] e. the native therapeutic factors
include bFGF, [0139] f. the native therapeutic factors include EGF,
[0140] g. the native therapeutic factors include MMP-9 and TIMP1,
[0141] h. the native therapeutic factors include MMP-9 and TIMP1 in
a ratio of about 7 to about 10, [0142] i. the placental product
does not comprise ex-vivo cultured cells, [0143] j. the
cryopreservative medium is present in an amount of greater than
about 20 ml or greater than about 50 ml, [0144] k. the
cryopreservative comprises DMSO, [0145] l. cryopreservative
comprises DMSO in a majority amount, [0146] m. the cryopreservation
medium further comprises albumin, optionally wherein the albumin is
HSA, [0147] n. the cryopreservative comprises DMSO and albumin
(e.g. HSA), [0148] o. comprises about 5,000 to about 240,000
cells/cm.sup.2 or about 20,000 to about 60,000, [0149] p. the
amniotic membrane comprises at least: about 2,000, or about 2,400,
or about 4,000 or about 6,000, or about 8,000, or about 10,000, or
about 10,585, or about 15,000 stromal cells per unit cm.sup.2 of
the amniotic membrane, [0150] q. the amniotic membrane comprises
about 2,000 to about 15,000 of stromal cells per cm.sup.2 of the
amniotic membrane, [0151] r. comprises stromal cells wherein at
least: about 40%, or about 50%, or about 60%, or about 70%, or
about 74.3%, or about 83.4 or about 90%, or about 92.5% of the
stromal cells are viable after a freeze-thaw cycle, [0152] s.
comprises stromal cells wherein about 40% to about 92.5% of the
stromal cells are viable after a freeze-thaw cycle, [0153] t. the
amniotic membrane has a thickness of about 20 .mu.m to about 50
.mu.m, [0154] u. secretes less than about any of: 420 .mu.g/mL, 350
.mu.g/mL, or 280 .mu.g/mL TNF-.alpha. into a tissue culture medium
upon placing a 2 cm.times.2 cm piece of the tissue product in a
tissue culture medium and exposing the tissue product to a
bacterial lipopolysaccharide for about 20 to about 24 hours, [0155]
v. cryopreservation and thawing, secretes less than about any of:
420 pg/mL, 350 pg/mL, or 280 pg/mL TNF-.alpha. into a tissue
culture medium upon placing a 2 cm.times.2 cm piece of the tissue
product in a tissue culture medium and exposing the tissue product
to a bacterial lipopolysaccharide for about 20 to about 24 hours,
[0156] w. after refrigeration, cryopreservation and thawing,
secretes less than about any of: 420 pg/mL, 350 pg/mL, or 280 pg/mL
TNF-.alpha. into a tissue culture medium upon placing a 2
cm.times.2 cm piece of the tissue product in a tissue culture
medium and exposing the tissue product to a bacterial
lipopolysaccharide for about 20 to about 24 hours, [0157] x.
further comprises an chorionic membrane, [0158] y. amniotic
membrane comprises a layer of amniotic epithelial cells, [0159] z.
further comprises an chorionic membrane, wherein the amniotic
membrane and the chorionic membrane are associated to one another
in the native configuration, [0160] aa. further comprises an
chorionic membrane, wherein the amniotic membrane and the chorionic
membrane are not attached to one another in the native
configuration, [0161] bb. further comprises a chorionic
membranewherein the chorionic membrane comprises about 2 to about 4
times more stromal cells relative to the amniotic membrane, [0162]
cc. does not comprise a chorionic membrane; [0163] dd. comprises
chorionic membrane, wherein the chorionic membrane comprises about
2 to about 4 times more stromal cells relative to the amniotic
membrane, and [0164] ee. is suitable for dermal application to a
wound;
[0165] Cells
[0166] According to the present invention, a placental product
comprises native therapeutic cells of the amniotic membrane. The
cells comprise one or more of stromal cells, MSCs, fibroblasts, and
epithelial cells.
[0167] In one embodiment, the native therapeutic cells comprise
viable stromal cells.
[0168] In one embodiment, the native therapeutic cells comprise
viable MSCs.
[0169] In one embodiment, the native therapeutic cells comprise
viable fibroblasts.
[0170] In one embodiment, the native therapeutic cells comprise
viable epithelial cells.
[0171] In one embodiment, the native therapeutic cells comprise
viable MSCs and viable fibroblasts.
[0172] In one embodiment, the native therapeutic cells comprise
viable MSCs, viable fibroblasts, and viable epithelial cells.
[0173] In one embodiment, the native therapeutic cells comprise
viable stromal cells and viable epithelial cells.
[0174] In one embodiment, the therapeutic native cells are viable
cells capable of differentiating into cells of more than one
lineage (e.g. osteogenic, adipogenic and/or chonodrogenic
lineages).
[0175] In one embodiment, the placental product comprises about
10,000 to about 360,000 or about 40,000 to about 90,000 cells per
cm.sup.2.
[0176] In one embodiment, the placental product comprises at least:
about 2,000, or about 2,400, or about 4,000, or about 6,000, or
about 8,000, or about 10,000, or about 10,585, or about 15,000
stromal cells per unit cm.sup.2 of the placental product.
[0177] In one embodiment, the placental product comprises about
2,000 to about 15,000 of stromal cells per cm.sup.2 of the
placental product.
[0178] In one embodiment, the placental product comprises stromal
cells wherein at least: about 40%, or about 50%, or about 60%, or
about 70%, or about 74.3%, or about 83.4 or about 90%, or about
92.5% of the stromal cells are viable after a freeze-thaw
cycle.
[0179] In one embodiment, the placental product comprises stromal
cells wherein about 40% to about 92.5% of the stromal cells are
viable after a freeze-thaw cycle.
[0180] In one embodiment, the placental product comprises less than
about 1% of CD14+ macrophages per total cells.
[0181] In one embodiment, the amniotic membrane of the placental
product comprises about 2 to about 4 times less stromal cells
relative to a chorionic membrane of the same area derived from the
same placenta.
[0182] In one embodiment, the placental product further comprises
membrane chorionic membrane containing about 2 to about 4 times
more stromal cells relative to the amniotic membrane.
[0183] In one embodiment, the amniotic membrane of the placental
product comprises MSCs in an amount of: at least about 1%, at least
about 2%, at least about 3%, at least about 4%, at least about 5%,
about 1% to about 10%, or about 3% to about 10%, relative to the
total number of cells in the amniotic membrane of the placental
product. Optionally, at least: about 40%, about 50%, about 60%, or
about 70% of the MSCs are viable after a freeze-thaw cycle.
[0184] In one embodiment, the amniotic membrane of the placental
product comprises fibroblasts in an amount of: about 1%, about 20%
, about 5% to about 15%, at least about 1%, at least about 2%, at
least about 3%, or at least about 4 relative to the total number of
cells in the amniotic membrane of the placental product.
Optionally, at least: about 40%, about 50%, about 60%, or about 70%
of the fibroblasts are viable after a freeze-thaw cycle.
[0185] In one embodiment, the amniotic membrane of the placental
product comprises stromal cells in an amount of: about 5% to about
40%, about 5% to about 30%, about 10% to about 30%, about 15% to
about 25%, at least about 5%, at least about 10%, or at least about
15%, relative to the total number of cells in the amniotic membrane
of the placental product. Optionally, at least: about 40%, about
50%, about 60%, or about 70% of the stromal cells are viable after
a freeze-thaw cycle.
[0186] In one embodiment, the amniotic membrane of the placental
product comprises epithelial cells in an amount of: about 60% to
about 90%, about 70% to about 90%, about 40% to about 90%, about
50% to about 90%, at least about 40%, at least about 50%, least
about 60%, or at least about 70%, relative to the total number of
cells in the amniotic membrane of the placental product.
Optionally, at least: about 40%, about 50%, about 60%, or about 70%
of the epithelial cells are viable after a freeze-thaw cycle.
[0187] In one embodiment, the amniotic membrane of the placental
product comprises MSCs and functional macrophages in a ratio of
greater than about any of: 5:1, 7:1, or 10:1.
[0188] In one embodiment, the amniotic membrane of the placental
product comprises fibroblasts and functional macrophages in a ratio
of greater than about any of: 10:1, 15:1, 20:1, or 25:1.
[0189] In one embodiment, the amniotic membrane of the placental
product comprises fibroblasts and MSCs in a ratio of: about 4:1 to
about 1:1 or about 3:1 to about 3:2, or about 2:1.
[0190] In one embodiment, the amniotic membrane of the placental
product comprises MSCs in an amount of: at least about 1,000
cells/cm.sup.2' at least about 2,000 cells/cm.sup.2, about 1,000 to
about 5,000 cells/cm.sup.2, or about 2,000 to about 5,000
cells/cm.sup.2. Optionally, at least: about 40%, about 50%, about
60%, or about 70% of the MSCs are viable after a freeze-thaw
cycle.
[0191] In one embodiment, the amniotic membrane of the placental
product comprises fibroblasts in an amount of: at least about 2,000
cells/cm.sup.2, at least about 4,000 cells/cm.sup.2, about 2,000 to
about 9,000 cells/cm.sup.2 , or about 2,000 to about 9,000
cells/cm.sup.2. Optionally, at least: about 40%, about 50%, about
60%, or about 70% of the fibroblasts are viable after a freeze-thaw
cycle.
[0192] In one embodiment, the amniotic membrane of the placental
product comprises stromal cells in an amount of: at least about
4,000, at least about 8,000 cells/cm.sup.2, about 4,000 to about
18,000 cells/cm.sup.2, or about 4,000 to about 18,000
cells/cm.sup.2. Optionally, at least: about 40%, about 50%, about
60%, or about 70% of the stromal cells are viable after a
freeze-thaw cycle.
[0193] In one embodiment, the amniotic membrane of the placental
product comprises epithelial cells in an amount of: at least about
10,000 cells/cm.sup.2, at least about 20,000 cells/cm.sup.2, at
least about 32,000 cells/cm.sup.2, about 10,000 to about 72,000
cells/cm.sup.2 , about 20,000 to about 72,000 cells/cm.sup.2 , or
about 32,000 to about 72,000 cells/cm.sup.2 Optionally, at least:
about 40%, about 50%, about 60%, or about 70% of the epithelial
cells are viable after a freeze-thaw cycle.
[0194] In one embodiment, the amniotic membrane of the placental
product comprises functional macrophages in an amount of: less than
about 3,000 cells/cm.sup.2, less than about 1,000 cells/cm.sup.2,
or less than about 500 cells/cm.sup.2.
[0195] In one embodiment, the placental product comprises a layer
of amniotic epithelial cells.
[0196] In one embodiment, the placental product comprises a
chorionic membrane but is substantially free of trophoblasts.
[0197] In one embodiment, the placental product is substantially
free of functional CD14+ macrophages.
[0198] In one embodiment, the placental product is substantially
free of vascularized tissue-derived cells.
[0199] In one embodiment, the placental product is substantially
free of trophoblasts, functional CD14+ macrophages, and
vascularized tissue-derived cells. Optionally, the placental
product comprises viable stromal cells. Optionally, the placental
product comprises viable MSCs. Optionally, the placental product
comprises viable fibroblasts. Optionally, the placental product
comprises viable epithelial cells. Optionally, the placental
product comprises viable MSCs, fibroblasts, and epithelial
cells.
[0200] In one embodiment, the placental product comprises a
chorionic membrane but is substantially free of maternal decidual
cells.
[0201] In one embodiment, the placental product comprises a
chorionic membrane but is substantially free of maternal leukocytes
and/or trophoblast cells.
[0202] In one embodiment, the placental product is substantially
free of ex-vivo cultured cells.
[0203] Placental Factors
[0204] According to the present invention, a placental product
comprises native therapeutic factors of the amniotic membrane.
[0205] In one embodiment, the factors include one or more of:
IGFBP1, adiponectin, .alpha.2-macroglobulin, bFGF, EGF, MMP-9, and
TIMP1. Optionally, the factors are present in amounts/cm.sup.2 that
are substantially similar to that of a native amniotic membrane or
layer thereof (e.g. .+-.10% or 20%).
[0206] In one embodiment, the factors include IGFBP1, adiponectin,
.alpha.2-macroglobulin, bFGF, EGF, MMP-9, and TIMP1. Optionally,
the factors are present in ratios that are substantially similar to
that of a native amniotic membrane or layer thereof. Optionally,
the factors are present in amounts/cm.sup.2 that are substantially
similar to that of a native amniotic membrane or layer thereof
(e.g. .+-.10% or 20%).
[0207] In one embodiment, the factors include MMP-9 and TIMP1 in a
ratio of about 7 to about 10 (e.g about 7). Optionally, the factors
are present in amounts/cm.sup.2 that are substantially similar to
that of a native amniotic membrane or layer thereof (e.g. .+-.10%
or 20%).
[0208] In one embodiment, the factors include one or more (e.g. a
majority or all) of the factors listed in Table 16. Optionally, the
factors are present in ratios that are substantially similar to
that of a native amniotic membrane or layer thereof. Optionally,
the factors are present in amounts/cm.sup.2 that are substantially
similar to that of a native amniotic membrane or layer thereof
(e.g. .+-.10% or 20%).
[0209] In one embodiment, the placental product or layer thereof
comprises substantially less TNF-.alpha./cm.sup.2 than a native
amniotic membrane or layer thereof, respectively.
[0210] In one embodiment, the placental product or layer thereof
secretes substantially less TNF-.alpha./cm.sup.2 than a native
placental product or layer thereof, respectively.
[0211] In one embodiment, the placental product secretes less than
about any of: 420 pg/mL, 350 pg/mL, or 280 pg/mL TNF-.alpha. into a
tissue culture medium upon placing a 2 cm.times.2 cm piece of the
tissue product in a tissue culture medium and exposing the tissue
product to a bacterial lipopolysaccharide for about 20 to about 24
hours.
[0212] In one embodiment, after cryopreservation and thawing, the
placental product secretes less than about any of: 420 pg/mL, 350
pg/mL, or 280 pg/mL TNF-.alpha. into a tissue culture medium upon
placing a 2 cm.times.2 cm piece of the tissue product in a tissue
culture medium and exposing the tissue product to a bacterial
lipopolysaccharide for about 20 to about 24 hours;
[0213] In one embodiment, after refrigeration, cryopreservation and
thawing, the placental product secretes less than about any of: 420
pg/mL, 350 pg/mL, or 280 pg/mL TNF-.alpha. into a tissue culture
medium upon placing a 2 cm.times.2 cm piece of the tissue product
in a tissue culture medium and exposing the tissue product to a
bacterial lipopolysaccharide for about 20 to about 24 hours.
[0214] In one embodiment, the placental product further comprises
an exogenously added inhibitor of TNF-.alpha.. Optionally, the
inhibitor of TNF-.alpha. is IL-10.
[0215] In one embodiment, the product has been treated with an
antibiotic
[0216] Architecture
[0217] A placental product of the present invention comprises one
or more layers which exhibit the architecture of the native
amniotic membrane. With the teachings provided herein, the skilled
artisan will recognize placental layers that exhibit native
architecture, for example, layers that have not been homogenized or
treated with collagenase or other enzyme that substantially
disrupts the layer.
[0218] In one embodiment, the placental product comprises a stromal
cell layer with native architecture of the amniotic membrane.
[0219] In one embodiment, the placental product comprises a
basement membrane with native architecture of the amniotic
membrane.
[0220] In one embodiment, the placental product comprises an
epithelial cell layer with native architecture of the amniotic
membrane.
[0221] In one embodiment, the placental product comprises a stromal
cell layer and a basement layer with native architecture of the
amniotic membrane.
[0222] In one embodiment, the placental product comprises a stromal
layer, a basement layer, and an epithelial cell layer with native
architecture of the amniotic membrane.
[0223] In one embodiment, the placental product or amniotic
membrane thereof has a thickness of about 20 .mu.m to about 50
.mu.m.
[0224] In one embodiment, the placental product comprises a
chorionic membrane but is substantially free of trophoblasts. In
one embodiment, the placental product comprises a basement membrane
with native architecture of the chorionic membrane and the
chorionic membrane is substantially free of trophoblasts.
Optionally, the maternal side of the chorionic membrane comprises
fragments of extracellular matrix proteins in a concentration
substantially greater than that of a native chorionic membrane.
Optionally, the placental product has been treated with Dispase
(e.g. Dispase II) and/or a substantial portion of the extracellular
matrix protein fragments comprises terminal leucine or
phenylalanine.
[0225] In one embodiment, the placental product further comprises a
chorionic membrane. Optionally, the amniotic membrane and the
chorionic membrane in the placental product are associated to one
another in the native configuration. Alternatively, the amniotic
membrane and the chorionic membrane are not attached to one another
in the native configuration.
[0226] In one embodiment, the placental product does not comprise a
chorionic membrane.
[0227] Formulation
[0228] According to the present invention, the placental product
can be formulated with a cryopreservation medium.
[0229] In one embodiment, the cryopreservation medium comprising
one or more cell-permeating cryopreservatives, one or more non
cell-permeating cryopreservatives, or a combination thereof.
[0230] Optionally, the cryopreservation medium comprises one or
more cell-permeating cryopreservatives selected from DMSO, a
glycerol, a glycol, a propylene glycol, an ethylene glycol, or a
combination thereof.
[0231] Optionally, the cryopreservation medium comprises one or
more non cell-permeating cryopreservatives selected from
polyvinylpyrrolidone, a hydroxyethyl starch, a polysacharide, a
monosaccharides, a sugar alcohol, an alginate, a trehalose, a
raffinose, a dextran, or a combination thereof.
[0232] Other examples of useful cryopreservatives are described in
"Cryopreservation" (BioFiles Volume 5 Number 4--Sigma-Aldrich.RTM.
datasheet).
[0233] In one embodiment, the cryopreservation medium comprises a
cell-permeating cryopreservative, wherein the majority of the
cell-permeating cryopreservative is DMSO. Optionally, the
cryopreservation medium does not comprise a substantial amount of
glycerol.
[0234] In one embodiment, the cryopreservation medium comprises
DMSO. Optionally, the cryopreservation medium does not comprise
glycerol in a majority amount. Optionally, the cryopreservation
medium does not comprise a substantial amount of glycerol.
[0235] In one embodiment, the cryopreservation medium comprises
additional components such as albumin (e.g. HSA or BSA), an
electrolyte solution (e.g. Plasma-Lyte), or a combination
thereof.
[0236] In one embodiment, the cryopreservation medium comprises 1%
to about 15% albumin by weight and about 5% to about 20%
cryopreservative by volume (e.g. about 10%). Optionally, the
cryopreservative comprises DMSO (e.g. in a majority amount).
[0237] In one embodiment, the placental product is formulated in
greater than about 20 ml or greater than about 50 ml of
cryopreservation medium. Optionally, the cryopreservative comprises
DMSO (e.g. in a majority amount). Optionally, the cryopreservation
medium does not comprise a substantial amount of glycerol.
[0238] In one embodiment, the placental product is placed on
nitrocellulose paper.
[0239] In one embodiment, the placenta is cut into a plurality of
sections. Optionally, the sections are less than about 10
cm.times.10 cm. Optionally, the sections are between about 2
cm.times.2 cm and 5 cm.times.5 cm.
[0240] Manufacture
[0241] Overview
[0242] A placental product of the present invention can
manufactured from a placenta in any suitable manner that provides
the technical features taught herein. According to the present
invention, a placenta product comprises at least an
immunocompatible amniotic membrane.
[0243] In one embodiment, a placental product is manufactured by a
method comprising: [0244] a. obtaining a placenta, [0245] b.
selectively depleting the placenta of immunogenicity; and [0246] c.
cryopreserving the placenta.
[0247] Optionally, the method comprises a step of removing
vascularized tissue from the placenta, for example, by lysing red
blood cells, by removing blood clots, or a combination thereof.
[0248] Optionally, the method comprises a step of treating the
placenta with one or more antibiotics.
[0249] Optionally, the method comprises a step of selectively
depleting CD14+ macrophages , optionally as demonstrated by a
substantial decrease in LPS stimulation of TNF.alpha. release.
[0250] Optionally, the step of cryopreserving the placenta
comprises freezing the placenta in a cryopreservation medium which
comprises one or more cell-permeating cryopreservatives, one or
more non cell-permeating cryopreservatives, or a combination
thereof.
[0251] Optionally, the step of cryopreserving the placenta
comprises refrigerating for a period of time and then freezing,
thereby selectively depleting CD14+ macrophages optionally as
demonstrated by a substantial decrease in LPS stimulation of
TNF.alpha. release.
[0252] Optionally, the method comprises retaining a layer of
epithelial cells of the amniotic membrane.
[0253] Optionally, the method comprises a step of removing the
chorionic membrane or portion thereof. Optionally, the method
comprises removing trophoblasts from the chorionic membrane while
retaining the stromal cell layer, reticular layer, and/or basement
membrane of the chorionic membrane.
[0254] An examplary placental product of the present invention can
be manufactured or provided with a bandage or wound dressing.
lmmunocompatability and Selective Depletion
[0255] In one embodiment, the invention the placental product is
immunocompatible. Immunocompatability can be accomplished by any
selective depletion step that removes immunogenic cells or factors
or immunogenicity from the placenta (or amniotic membrane
thereof).
[0256] In one embodiment, the placental product is made
immunocompatible by selectively depleting it of functional
immunogenic cells. A placenta can be made immunocompatible by
selectively removing immunogenic cells from the placenta (or
amniotic membrane thereof) relative to therapeutic cells. For
example, immunogenic cells can be removed by killing the
immunogenic cells or by purification of the placenta there
from.
[0257] In one embodiment, the placental product is made
immunocompatible by selectively depleting trophoblasts, for
example, by removal of the trophoblast layer.
[0258] In one embodiment, the placenta is made immunocompatible by
selective depletion of functional CD14+ macrophages, optionally as
demonstrated by a substantial decrease in LPS stimulation of
TNF.alpha. release or by MLR assay.
[0259] In one embodiment, the placenta is made immunocompatible by
selective depletion of vascularized tissue-derived cells.
[0260] In one embodiment, the placenta is made immunocompatible by
selective depletion of functional CD14+ macrophages, trophoblasts,
and vascularized tissue-derived cells.
[0261] In one embodiment, the placenta product is made
immunocompatible by selective depletion of trophoblasts and/or
CD14+ macrophages, optionally as demonstrated by a substantial
decrease in LPS stimulation of TNF.alpha. release or by MLR
assay.
[0262] Trophoblast Removal
[0263] In one embodiment, Immunocompatability (or selective
depletion) is accomplished by removal or depletion of trophoblasts
from the placental product. Trophoblasts can be removed by removing
the chorionic membrane from the placental product or by removing
trophoblasts from the chorionic membrane while retaining at least
one of the basement layer, reticular layer, or stromal cell layer
of the chorionic membrane. Surprisingly, such a placental product
has one or more of the following superior features: [0264] a. is
substantially non-immunogenic; [0265] b. provides remarkable
healing time; and [0266] c. provides enhanced therapeutic
efficacy.
[0267] In one embodiment, trophoblasts are removed while retaining
the basement layer, reticular layer, and/or stromal cell layer of
the chorionic membrane.
[0268] Trophoblasts can be removed in any suitable manner which
substantially diminishes the trophoblast content of the placental
product. Optionally, the trophoblasts are selectively removed or
otherwise removed without eliminating a substantial portion of one
or more therapeutic components from the chorionic membrane (e.g.
MSCs, placental factors, etc). Optionally, a majority (e.g.
substantially all) of the trophoblasts are removed.
[0269] One method of removing trophoblasts comprises treating the
placenta (e.g. chorion or amnio-chorion) with a digestive enzyme
such as dispase (e.g. dispase II) and separating the trophoblasts
from the placenta. Optionally, the step of separating comprises
mechanical separation such as peeling or scraping. Optionally,
scraping comprises scraping with a soft instrument such as a
finger.
[0270] One method of removing trophoblasts comprises treating the
chorionic membrane with dispase for about 30 to about 45 minutes
separating the trophoblasts from the placenta. Optionally, the
dispase is provided in a solution of about less than about 1% (e.g.
about 0.5%). Optionally, the step of separating comprises
mechanical separation such as peeling or scraping. Optionally,
scraping comprises scraping with a soft instrument such as a
finger.
[0271] Useful methods of removing trophoblasts from a placenta
(e.g. chorion) are described by Portmann-Lanz et al. ("Placental
mesenchymal stem cells as potential autologous graft for pre- and
perinatal neuroregeneration"; American Journal of Obstetrics and
Gynecology (2006) 194, 664-73), ("Isolation and characterization of
mesenchymal cells from human fetal membranes"; Journal Of Tissue
Engineering And Regenerative Medicine 2007; 1: 296-305.), and
(Concise Review: Isolation and Characterization of Cells from Human
Term Placenta: Outcome of the First International Workshop on
Placenta Derived Stem Cells").
[0272] In one embodiment, trophoblasts are removed before
cryopreservation.
[0273] Macrophage Removal
[0274] In one embodiment, functional macrophages are depleted or
removed from the placental product. Surprisingly, such a placental
product has one or more of the following superior features: [0275]
a. is substantially non-immunogenic; [0276] b. provides remarkable
healing time; and [0277] c. provides enhanced therapeutic
efficacy.
[0278] Functional macrophages can be removed in any suitable manner
which substantially diminishes the macrophage content of the
placental product. Optionally, the macrophages are selectively
removed or otherwise removed without eliminating a substantial
portion of one or more therapeutic components from the placenta
(e.g. MSCs, placental factors, etc). Optionally, a majority (e.g.
substantially all) of the macrophages are removed.
[0279] One method of removing immune cells such as macrophages
comprises killing the immune cells by rapid freezing rates such as
60-100.degree. C./min.
[0280] Although immune cells can be eliminated by rapid freezing
rates, such a method can also be detrimental to therapeutic cells
such as stromal cells (e.g. MSCs). The present inventors have
discovered a method of selectively killing CD14+ macrophages can be
selectively killed by refrigerating the placenta for a period of
time (e.g. for at least about 10 min such as for about 30-60 mins)
at a temperature above freezing (e.g. incubating at 2-8.degree. C.)
and then freezing the placenta (e.g. incubating at -80.degree.
C..+-.5.degree. C.). Optionally, the step of freezing comprises
freezing at a rate of less than 10.degree./min (e.g. less than
about 5.degree./min such as at about 1.degree./min).
[0281] In one embodiment, the step of refrigerating comprises
soaking the placenta in a cryopreservation medium (e.g. containing
DMSO) for a period of time sufficient to allow the cryopreservation
medium to penetrate (e.g. equilibrate with) the placental tissues.
Optionally, the step of freezing comprises reducing the temperature
at a rate of about 1.degree./min. Optionally, the step of freezing
comprises freezing at a rate of less than 10.degree./min (e.g. less
than about 5.degree./min such as at about 1.degree./min).
[0282] In one embodiment, the step of refrigerating comprises
soaking the placenta in a cryopreservation medium (e.g. containing
DMSO) at a temperature of about -10-15.degree. C. (e.g. at
2-8.degree. C.) for at least about any of: 10 min, 20 min, 30 min,
40 min, or 50 min. In another embodiment the step of refrigerating
comprises soaking the placenta in a cryopreservation medium (e.g.
containing DMSO) at a temperature of about -10-15.degree. C. (e.g.
at 2-8.degree. C.) for about any of: 10-120, 20-90 min, or 30-60
min. Optionally, the step of freezing comprises freezing at a rate
of less than 10.degree./min (e.g. less than about 5.degree./min
such as at about 1.degree./min).
[0283] Removal of Vascularized Tissue-Derived Cells
[0284] In one embodiment, vascularized tissue-derived cells (or
vascularized tissue) are depleted or removed from the placental
product. Surprisingly, such a placental product has one or more of
the following superior features: [0285] a. is substantially
non-immunogenic; [0286] b. provides remarkable healing time; and
[0287] c. provides enhanced therapeutic efficacy.
[0288] Vascularized tissue-derived cells can be removed in any
suitable manner which substantially diminishes such cell content of
the placental product. Optionally, the vascularized tissue-derived
cells are selectively removed or otherwise removed without
eliminating a substantial portion of one or more therapeutic
components from the placenta (e.g. MSCs, placental factors,
etc).
[0289] In one embodiment, removal of vascularized tissue-derived
cells comprises rinsing the amniotic membrane (e.g. with buffer
such as PBS) to remove gross blood clots and any excess blood
cells.
[0290] In one embodiment, removal of vascularized tissue-derived
cells comprises treating the amniotic membrane with an
anticoagulant (e.g. citrate dextrose solution).
[0291] In one embodiment, removal of vascularized tissue-derived
cells comprises rinsing the amniotic membrane (e.g. with buffer
such as PBS) to remove gross blood clots and any excess blood
cells, and treating the amniotic membrane with an anticoagulant
(e.g. citrate dextrose solution).
[0292] In one embodiment, the chorionic membrane is retained and
removal of vascularized tissue-derived cells comprises separating
the chorion from the placenta by cutting around the placental skirt
on the side opposite of the umbilical cord. The chorion on the
umbilical side of the placenta is not removed due to the
vascularization on this side.
[0293] In one embodiment, the chorionic membrane is retained and
removal of vascularized tissue-derived cells comprises separating
the chorion from the placenta by cutting around the placental skirt
on the side opposite of the umbilical cord and rinsing the amniotic
membrane and chorionic membrane (e.g. with buffer such as PBS) to
remove gross blood clots and any excess blood cells.
[0294] In one embodiment, the chorionic membrane is retained and
removal of vascularized tissue-derived cells comprises separating
the chorion from the placenta by cutting around the placental skirt
on the side opposite of the umbilical cord and treating the
amniotic membrane and chorionc membrane with an anticoagulant (e.g.
citrate dextrose solution).
[0295] In one embodiment, the chorionic membrane is retained and
emoval of vascularized tissue-derived cells comprises separating
the chorion from the placenta by cutting around the placental skirt
on the side opposite of the umbilical cord, rinsing the chorionic
membrane amniotic membrane (e.g. with buffer such as PBS) to remove
gross blood clots and any excess blood cells, and treating the
amniotic membrane with an anticoagulant (e.g. citrate dextrose
solution).
[0296] Selective Depletion of Immunogenicity as Demonstrated by a
Substantial Decrease in LPS Stimulation of TNF.alpha. Release.
[0297] In one embodiment, the placental product is selectively
depleted of immunogenicity as demonstrated by a reduction in LPS
stimulated TNF-.alpha. release. In one embodiment, the placental
product is selectively depleted of macrophages.
[0298] In one embodiment, TNF-.alpha. is depleted by killing or
removal of macrophages.
[0299] In one embodiment, TNF-.alpha. is functionally depleted by
treatment with IL-10, which suppresses TNF-.alpha. secretion.
[0300] Preservation
[0301] A placental product of the present invention may be used
fresh or may be preserved for a period of time. Surprisingly,
cryopreservation results in immunocompatible placental
products.
[0302] In one embodiment, a placental product is cryopreserved. A
placental product may be cryopreserved by incubation at freezing
temperatures (e.g. a -80.degree. C..+-.5.degree. C.) in a
cryopreservative medium.
[0303] Cryopreservation can comprise, for example, incubating the
placental product at 4.degree. C. for 30-60 min, and then
incubating at -80.degree. C. until use. The placental product may
then be thawed for use. Optionally, the placental product is
cryopreserved in a manner such that cell viability is retained
surprisingly well after a freeze-thaw cycle.
[0304] In one embodiment, cryopreservation comprises storage in a
cryopreservation medium comprising one or more cell-permeating
cryopreservatives, one or more non cell-permeating
cryopreservatives, or a combination thereof. Optionally, the
cryopreservation medium comprises one or more cell-permeating
cryopreservatives selected from DMSO, a glycerol, a glycol, a
propylene glycol, an ethylene glycol, or a combination thereof.
Optionally, the cryopreservation medium comprises one or more non
cell-permeating cryopreservatives selected from
polyvinylpyrrolidone, a hydroxyethyl starch, a polysacharide, a
monosaccharides, a sugar alcohol, an alginate, a trehalose, a
raffinose, a dextran, or a combination thereof. Other examples of
useful cryopreservatives are described in "Cryopreservation"
(BioFiles Volume 5 Number 4--Sigma-Aldrich.RTM. datasheet).
[0305] In one embodiment, the cryopreservation medium comprises a
cell-permeating cryopreservative, wherein the majority of the
cell-permeating cryopreservative is DMSO. Optionally, the
cryopreservation medium does not comprise a substantial amount of
glycerol.
[0306] In one embodiment, the cryopreservation medium comprises
DMSO. Optionally, the cryopreservation medium does not comprise
glycerol in a majority amount. Optionally, the cryopreservation
medium does not comprise a substantial amount of glycerol.
[0307] In one embodiment, the cryopreservation medium comprises
additional components such as albumin (e.g. HSA or BSA), an
electrolyte solution (e.g. Plasma-Lyte), or a combination
thereof.
[0308] In one embodiment, the cryopreservation medium comprises 1%
to about 15% albumin by weight and about 5% to about 20%
cryopreservative by volume (e.g. about 10%). Optionally, the
cryopreservative comprises DMSO (e.g. in a majority amount).
[0309] In one embodiment, cryopreservation comprises placing the
placenta on nitrocellulose paper.
[0310] In one embodiment, the placenta is cut into a plurality of
sections before cryopreservation. Optionally, the sections are
placed on nitrocellulose paper before refrigeration.
[0311] Methods of Use
[0312] The placental products of the present invention may be used
to treat any tissue injury. A method of treatment may be provided,
for example, by administering to a subject in need thereof, a
placental product of the present invention.
[0313] A typical administration method of the present invention is
topical administration. Administering the present invention can
optionally involve administration to an internal tissue where
access is gained by a surgical procedure.
[0314] Placental products can be administered autologously,
allogeneically or xenogeneically.
[0315] In one embodiment, a present placental product is
administered to a subject to treat a wound. Optionally, the wound
is a laceration, scrape, thermal or chemical burn, incision,
puncture, or wound caused by a projectile. Optionally, the wound is
an epidermal wound, skin wound, chronic wound, acute wound,
external wound, internal wounds, congenital wound, ulcer, or
pressure ulcer. Such wounds may be accidental or deliberate, e.g.,
wounds caused during or as an adjunct to a surgical procedure.
Optionally, the wound is closed surgically prior to
administration.
[0316] In one embodiment, a present placental product is
administered to a subject to treat a burn. Optionally, the burn is
a first-degree burn, second-degree burn (partial thickness burns),
third degree burn (full thickness burns), infection of burn wound,
infection of excised and unexcised burn wound, loss of epithelium
from a previously grafted or healed burn, or burn wound
impetigo.
[0317] In one embodiment, a present placental product is
administered to a subject to treat an ulcer, for example, a
diabetic ulcer (e.g. foot ulcer).
[0318] In one embodiment, a placental product is administered by
placing the placental product directly over the skin of the
subject, e.g., on the stratum corneum, on the site of the wound, so
that the wound is covered, for example, using an adhesive tape.
Additionally or alternatively, the placental product may be
administered as an implant, e.g., as a subcutaneous implant.
[0319] In one embodiment, a placental product is administered to
the epidermis to reduce rhtids or other features of aging skin.
Such treatment is also usefully combined with so-called cosmetic
surgery (e.g. rhinoplasty, rhytidectomy, etc.).
[0320] In one embodiment, a placental product is administered to
the epidermis to accelerate healing associated with a dermal
ablation procedure or a dermal abrasion procedure (e.g. including
laser ablation, thermal ablation, electric ablation, deep dermal
ablation, sub-dermal ablation, fractional ablation, and microdermal
abrasion).
[0321] Other pathologies that may be treated with placental
products of the present invention include traumatic wounds (e.g.
civilian and military wounds), surgical scars and wounds, spinal
fusions, spinal cord injury, avascular necrosis, reconstructive
surgeries, ablations, and ischemia.
[0322] In one embodiment, a placental product of the present
invention is used in a tissue graft procedure. Optionally, the
placental product is applied to a portion of the graft which is
then attached to a biological substrate (e.g. to promote healing
and/or attachment to the substrate). By way of non-limiting
example, tissues such as skin, cartilage, ligament, tendon,
periosteum, perichondrium, synovium, fascia, mesenter and sinew can
be used as tissue graft.
[0323] In one embodiment, a placental product is used in a tendon
or ligament surgery to promote healing of a tendon or ligament.
Optionally, the placental product is applied to portion of a tendon
or ligament which is attached to a bone. The surgery can be any
tendon or ligament surgery, including, e.g. knee surgery, shoulder,
leg surgery, arm surgery, elbow surgery, finger surgery, hand
surgery, wrist surgery, toe surgery, foot surgery, ankle surgery,
and the like. For example, the placental product can be applied to
a tendon or ligament in a grafting or reconstruction procedure to
promote fixation of the tendon or ligament to a bone.
[0324] Through the insight of the inventors, it has surprisingly
been discovered that placental products of the present invention
provide superior treatment (e.g. healing time and/or healing
strength) for tendon and ligament surgeries. Tendon and ligament
surgeries can involve the fixation of the tendon or ligament to
bone. Without being bound by theory, the present inventors believe
that osteogenic and/or chondrogenic potential of MSCs in the
present placental products promotes healing process and healing
strength of tendons or ligaments. The present inventors believe
that the present placental products provide an alternative or
adjunctive treatment to periosteum-based therapies. For example,
useful periosteum based treatments are described in Chen et al.
("Enveloping the tendon graft with periosteum to enhance
tendon-bone healing in a bone tunnel: A biomechanical and
histologic study in rabbits"; Arthroscopy. 2003 Mar;19(3):290-6),
Chen et al. ("Enveloping of periosteum on the hamstring tendon
graft in anterior cruciate ligament reconstruction"; Arthroscopy.
2002 May-June; 18(5):27E), Chang et al. ("Rotator cuff repair with
periosteum for enhancing tendon-bone healing: a biomechanical and
histological study in rabbits"; Knee Surgery, Sports Traumatology,
Arthroscopy Volume 17, Number 12, 1447-1453), each of which are
incorporated by reference.
[0325] As non-limiting example of a method of tendon or ligament
surgery, a tendon is sutured to and/or wrapped or enveloped in a
placental membrane and the tendon is attached to a bone.
Optionally, the tendon is placed into a bone tunnel before attached
to the bone.
[0326] In one embodiment, the tendon or ligament surgery is a graft
procedure, wherein the placental product is applied to the graft.
Optionally, the graft is an allograft, xenograft, or an autologous
graft.
[0327] In one embodiment, the tendon or ligament surgery is repair
of a torn ligament or tendon, wherein the placental product is
applied to the torn ligament or tendon.
[0328] Non-limiting examples of tendons to which a placental
product can be applied include a digitorum extensor tendon, a
hamstring tendon, a bicep tendon, an Achilles Tendon, an extensor
tendon, and a rotator cuff tendon.
[0329] In one embodiment, a placental product of the present
invention is used to reduce fibrosis by applying the placental
product to a wound site.
[0330] In one embodiment, a placental product of the present
invention is used as an anti-adhesion wound barrier, wherein the
placental product is applied to a wound site, for example, to
reduce fibrosis (e.g. postoperative fibrosis).
[0331] Non-limiting examples of wound sites to which the placental
product can be applied include those that are surgically induced or
associated with surgery involving the spine, laminectomy, knee,
shoulder, or child birth, trauma related wounds or injuries,
cardiovascular procedures, angiogenesis stimulation,
brain/neurological procedures, burn and wound care, and ophthalmic
procedures. For example, optionally, the wound site is associated
with surgery of the spine and the stromal side of the placental
product is applied to the dura (e.g. the stromal side facing the
dura). Direction for such procedures, including the selection of
wound sites and/or methodologies, can be found, for example, in WO
2009/132186 and US 2010/0098743, which are hereby incorporated by
reference.
[0332] A placental product of the present invention can optionally
be used to reduce adhesion or fibrosis of a wound. Postoperative
fibrosis is a natural consequence of all surgical wound healing. By
example, postoperative peridural adhesion results in tethering,
traction, and compression of the thecal sac and nerve roots, which
cause a recurrence of hyperesthesia that typically manifests a few
months after laminectomy surgery. Repeated surgery for removal of
scar tissue is associated with poor outcome and increased risk of
injury because of the difficulty of identifying neural structures
that are surrounded by scar tissue. Therefore, experimental and
clinical studies have primarily focused on preventing the adhesion
of scar tissue to the dura matter and nerve roots. Spinal adhesions
have been implicated as a major contributing factor in failure of
spine surgery. Fibrotic scar tissue can cause compression and
tethering of nerve roots, which can be associated with recurrent
pain and physical impairment.
[0333] Without being bound by theory, the present inventors believe
that placental products taught herein are useful to reduce adhesion
or fibrosis of a wound, at least in part, because the placental
products can perform the very critical function in-situ of
providing a immunoprivileged environment (i.e. relatively high
resistance against immune responses) in the human development
process. One advantage of the wound dressings and processes of the
present invention is that an anti-adhesion barrier is provided
which can be used to prevent adhesions following surgery, and in
particular following back surgery.
[0334] In the preceding paragraphs, use of the singular may include
the plural except where specifically indicated. As used herein, the
words "a," "an," and "the" mean "one or more," unless otherwise
specified. In addition, where aspects of the present technology are
described with reference to lists of alternatives, the technology
includes any individual member or subgroup of the list of
alternatives and any combinations of one or more thereof.
[0335] The disclosures of all patents and publications, including
published patent applications, are hereby incorporated by reference
in their entireties to the same extent as if each patent and
publication were specifically and individually incorporated by
reference.
[0336] It is to be understood that the scope of the present
technology is not to be limited to the specific embodiments
described above. The present technology may be practiced other than
as particularly described and still be within the scope of the
accompanying claims.
[0337] Likewise, the following examples are presented in order to
more fully illustrate the present technology. They should in no way
be construed, however, as limiting the broad scope of the
technology disclosed herein.
[0338] The presently described technology and its advantages will
be better understood by reference to the following examples. These
examples are provided to describe specific embodiments of the
present technology. By providing these specific examples, it is not
intended limit the scope and spirit of the present technology. It
will be understood by those skilled in the art that the full scope
of the presently described technology encompasses the subject
matter defined by the claims appending this specification, and any
alterations, modifications, or equivalents of those claims.
EXAMPLES
[0339] Other features and embodiments of the present technology
will become apparent from the following examples which are given
for illustration of the present technology rather than for limiting
its intended scope.
Example 1
Characterization of Placental Membranes
[0340] Cells in placental membranes were characterized by
Fluorescence Activated Cell Sorting (FACS) demonstrated the
presence of stromal cells (Mesenchymal Stem Cell-like cells) in
addition to fetal epithelial cells and fibroblasts.
[0341] One unique characteristic of the presently disclosed
placental products is the presence of MSCs, which have been shown
to be one of three types of cells (in addition to epithelial cells
and fibroblasts) that are important for wound healing. Placental
membranes secrete a variety of factors involved in wound healing
such as angiogenic factors, factors supporting proliferation and
migration of epithelial cells and fibroblasts, factors attracting
endothelial stem cells from blood circulation to the wound site,
antibacterial factors, and others.
[0342] Evaluation of proteins secreted by examplary placental
products of the invention in comparison to Apligraf and Dermagraft
demonstrated a number of growth factors present in the tested
products that are involved in wound healing. Examples are Vascular
Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor
(PDGF), Transforming Growth Factor (TGF) and others. However,
several unique factors including Epidermal Growth Factor (EGF),
which is one of the key factors for wound healing, are present in
placental membranes and absent in Apligraf and Dermagraft. Also,
placental membranes have a favorable protease-to-protease inhibitor
ratio for wound healing. In an in vitro model of wound healing
(cell migration assay, disclosed herein), the present inventors
have demonstrated that placental membranes secrete factors
promoting cell migration that will support wound closure.
Example 2
Exemplary Manufacturing Process of a Placental Product
[0343] In one embodiment, the present invention is a method of
manufacturing a placental product comprising an amniotic membrane
and optionally a chorionic membrane from placenta post partum. One
such method is: [0344] a. Remove umbilical cord close to placental
surface, [0345] b. Blunt dissect of the amnion to placental skirt,
[0346] c. Flip placenta over and completely remove amnion, [0347]
d. Rinse amnion in PBS to remove red blood cells, [0348] e. Rinse
amnion once with 11% ACD-A solution to assist in red blood cell
removal, [0349] f. Rinse amnion with PBS to remove ACD-A solution,
[0350] g. Use PBS to remove any remaining blood from the amnion,
[0351] h. Gently remove the connective tissue layer from the
amnion, [0352] i. Place the amnion in PBS and set aside, [0353] j.
Place the amnion into a bottle containing antibiotic solution and
incubate at 37.degree. C. .+-.2.degree. C. for 24-28 hrs, [0354] k.
Remove bottle from the incubator and rinse membrane with PBS to
remove antibiotic solution, [0355] l. Mount amnion (epithelial side
up) on reinforced nitrocellulose paper and cut to size, [0356] m.
Place into an FP-90 cryobag and heat seal, [0357] n. Add 50 mL
cryopreservation solution to the bag through a syringe and remove
any air trapped within the bag with the syringe, [0358] o. Tube
seal the solution line on the FP-90 bag, [0359] p. Place filled bag
into secondary bag and heat seal, [0360] q. Place unit into
packaging carton, [0361] r. Refrigerate at 2-8.degree. C. for 30-60
minutes, Freeze at -80.degree. C..+-.5.degree. C. inside a
Styrofoam container.
Example 3
Exemplary Manufacturing Process of a Placental Product Containing
an Amniotic Membrane and a Chorionic Membrane
[0362] In one embodiment, the present invention is a method of
manufacturing a placental product comprising an amniotic membrane
and optionally a chorionic membranes from placenta post partum. One
such method is: [0363] a. Remove umbilical cord close to placental
surface, [0364] b. Blunt dissect of the amnion to placental skirt,
[0365] c. Flip placenta over and completely remove amnion, [0366]
d. Remove chorion by cutting around placental skirt, [0367] e.
Rinse both membranes in PBS to remove red blood cells, [0368] f.
Rinse both membranes once with 11% ACD-A solution to assist in red
blood cell removal, [0369] g. Rinse both membranes with PBS to
remove ACD-A solution, \ [0370] h. Treat chorion in 0.5% dispase
solution at 37.degree. C..+-.2.degree. C. for 30-45 minutes,
optionally, during dispase incubation period, use PBS to remove any
remaining blood from the amnion, [0371] i. Gently remove the
connective tissue layer from the amnion, [0372] j. Place the amnion
in PBS and set aside, [0373] k. When dispase treatment is complete,
rinse chorion with PBS to remove dispase solution, [0374] l. Gently
remove trophoblast layer from the chorion, [0375] m. Place the
amnion and chorion each into a bottle containing antibiotic
solution and incubate at 37.degree. C..+-.2.degree. C. for 24-28
hrs, [0376] n. Remove bottles from the incubator and rinse each
membrane with PBS to remove antibiotic solution, [0377] o. Mount
amnion (epithelial side up) or chorion on reinforced nitrocellulose
paper and cut to size, [0378] p. Place each piece into an FP-90
cryobag and heat seal, [0379] q. Add 50 mL cryopreservation
solution to the bag through a syringe and remove any air trapped
within the bag with the syringe, [0380] r. Tube seal the solution
line on the FP-90 bag, [0381] s. Place filled bag into secondary
bag and heat seal, [0382] t. Place unit into packaging carton,
[0383] u. Refrigerate at 2-8.degree. C. for 30-60 minutes, [0384]
v. Freeze at -80.degree. C..+-.5.degree. C. inside a Styrofoam
container.
Example 4
Exemplary Placental Product Manufacturing Process
[0385] One method manufacturing a placental product comprising an
amniotic membrane according to the presently disclosed
manufacturing procedure is as follows:
[0386] One method of manufacturing a placental product comprising a
chorionic membrane product and an amniotic membrane product
according to the presently disclosed manufacturing procedure was as
follows:
[0387] The placenta was processed inside a biological safety
cabinet. The umbilical cord was first removed, and the amniotic
membrane was peeled from the underlying chorionic membrane using
blunt dissection. The membrane was rinsed with phosphate buffered
saline (PBS) (Gibco Invitrogen, Grand Island, N.Y.) to remove gross
blood clots and any excess blood cells. The membrane was then
washed with 11% anticoagulant citrate dextrose solution (USP)
formula A (ACD-A) (Baxter Healthcare Corp., Deerfield, Ill.) in
saline (Baxter Healthcare Corp., Deerfield, Ill.) to remove
remaining blood cells.
[0388] The stromal side of the amnion was cleaned by gently
scraping away any remaining connective tissue.
[0389] The amnion was then each disinfected in 500 mL of antibiotic
solution consisting of gentamicin sulfate (50 .mu.g/mL) (Abraxis
Pharmaceutical Products, Schaumburg, Ill.), vancomycin HCI (50
.mu.g/mL) (Hospira Inc., Lake Forest, Ill.), and amphotericin B
(2.5 .mu.g/mL) (Sigma Aldrich, St. Louis, Mo.) in DMEM at
37.degree. C..+-.2.degree. C. for 24-28 hours. Vented caps were
used with the incubation flasks. After the incubation period, the
membrane was washed with PBS to remove any residual antibiotic
solution.
[0390] The membrane was mounted on Optitran BA-S 85 reinforced
nitrocellulose paper (Whatman, Dassel, Germany) and cut to the
appropriate size prior to packaging into an FP-90 cryobag (Charter
Medical Ltd., Winston-Salem, N.C.). The stromal side of the amnion
was mounted towards the nitrocellulose paper. Once the membrane
unit was placed into the FP-90 cryobag and the cryobag was heat
sealed, 50 mL of a cryopreservation solution containing 10%
dimethyl sulfoxide (DMSO) (Bioniche Teo. Inverin Co., Galway,
Ireland) and 5% human serum albumin (HSA) (Baxter, West Lake
Village, Calif.) in PlasmaLyte-A (Baxter Healthcare Corp.,
Deerfield, Ill.) were added through the center tubing line. Any
excess air was removed, and the tubing line was subsequently
sealed.
[0391] The FP-90 cryobag was placed into a mangar bag (10
in..times.6 in.) (Mangar Industries, New Britain, PA), which was
then heat sealed. The mangar bag was placed into a packaging carton
(10.5 in..times.6.5 in..times.0.6 in.) (Diamond Packaging,
Rochester, N.Y.). All cartons were refrigerated at 2-8.degree. C.
for 30-60 minutes prior to freezing at -80.degree. C..+-.5.degree.
C. inside a Styrofoam container.
Example 5
Exemplary Manufacturing Process of a Placental Product Comprising
Chorionic Membrane and Amniotic Membrane
[0392] One method of manufacturing a placental product comprising a
chorionic membrane product and an amniotic membrane product
according to the presently disclosed manufacturing procedure was as
follows:
[0393] The placenta was processed inside a biological safety
cabinet. The umbilical cord was first removed, and the amniotic
membrane was peeled from the underlying chorionic membrane using
blunt dissection. Subsequently, the chorion was removed by cutting
around the placental skirt on the side opposite of the umbilical
cord. The chorion on the umbilical side of the placenta was not
removed due to the vascularization on this side. Both membranes
were rinsed with phosphate buffered saline (PBS) (Gibco Invitrogen,
Grand Island, N.Y.) to remove gross blood clots and any excess
blood cells. The membranes were then washed with 11% anticoagulant
citrate dextrose solution (USP) formula A (ACD-A) (Baxter
Healthcare Corp., Deerfield, Ill.) in saline (Baxter Healthcare
Corp., Deerfield, Ill.) to remove remaining blood cells.
[0394] The chorion was then incubated in 200 mL of a 0.5% dispase
(BD Biosciences, Bedford, MA) solution in Dulbecco's modified
eagles media (DMEM) (Lonza, Walkersville, Md.) at 37.degree.
C..+-.2.degree. C. for 30-45 minutes to digest the connective
tissue layer between the chorion and adjacent trophoblast layer.
During this incubation period, the stromal side of the amnion was
cleaned by gently scraping away any remaining connective tissue.
Once the chorion incubation period was complete, the chorion was
rinsed with PBS to remove the dispase solution. Subsequently, the
trophoblast layer was removed by gently peeling or scraping away
these maternal decidual cells.
[0395] The amnion and chorion were then each disinfected in 500 mL
of antibiotic solution consisting of gentamicin sulfate (50
.mu.g/mL) (Abraxis Pharmaceutical Products, Schaumburg, Ill.),
vancomycin HCl (50 .mu.g/mL) (Hospira Inc., Lake Forest, Ill.), and
amphotericin B (2.5 .mu.g/mL) (Sigma Aldrich, St. Louis, Mo.) in
DMEM at 37.degree. C..+-.2.degree. C. for 24-28 hours. Vented caps
were used with the incubation flasks. After the incubation period,
the membranes were washed with PBS to remove any residual
antibiotic solution.
[0396] The membranes were mounted on Optitran BA-S 85 reinforced
nitrocellulose paper (Whatman, Dassel, Germany) and cut to the
appropriate size prior to packaging into an FP-90 cryobag (Charter
Medical Ltd., Winston-Salem, N.C.). For the amnion, the stromal
side was mounted towards the nitrocellulose paper. Once a membrane
unit was placed into the FP-90 cryobag and the cryobag was heat
sealed, 50 mL of a cryopreservation solution containing 10%
dimethyl sulfoxide (DMSO) (Bioniche Teo. Inverin Co., Galway,
Ireland) and 5% human serum albumin (HSA) (Baxter, West Lake
Village, Calif.) in PlasmaLyte-A (Baxter Healthcare Corp.,
Deerfield, Ill.) were added through the center tubing line. Any
excess air was removed, and the tubing line was subsequently
sealed.
[0397] The FP-90 cryobag was placed into a mangar bag (10
in..times.6 in.) (Mangar Industries, New Britain, PA), which was
then heat sealed. The mangar bag was placed into a packaging carton
(10.5 in..times.6.5 in..times.0.6 in.) (Diamond Packaging,
Rochester, N.Y.). All cartons were refrigerated at 2-8.degree. C.
for 30-60 minutes prior to freezing at -80.degree. C..+-.5.degree.
C. inside a Styrofoam container.
Example 6
Quantitative Evaluation of Cell Number and Cell Viability after
Enzymatic Digestion of Placental Membranes
[0398] Amnion and chorion membranes and present placental products
(from above) were evaluated for cell number and cell viability
throughout the process. These analyses were performed on fresh
placental tissue (prior to the antibiotic treatment step),
placental tissue post antibiotic treatment, and product units post
thaw. Cells were isolated from the placental membranes using
enzymatic digestion. For the frozen product units, the FP-90
cryobags were first removed from the packaging cartons and mangar
bags. Then the FP-90 cryobags were thawed for 2-3 minutes in a room
temperature water bath. Early experiments involved the use of a
37.degree. C..+-.2.degree. C. water bath. After thaw, the placental
membranes were removed from the FP-90 cryobag and placed into a
reservoir containing saline (Baxter Healthcare Corp., Deerfield,
Ill.) for a minimum of 1 minute and a maximum of 60 minutes. Each
membrane was detached from the reinforced nitrocellulose paper
prior to digestion.
[0399] Amniotic membranes were digested with 40 mL of 0.75%
collagenase (Worthington Biochemical Corp., Lakewood, NJ) solution
at 37.degree. C..+-.2.degree. C. for 20-40 minutes on a rocker.
After collagenase digestion, the samples were centrifuged at 2000
rpm for 10 minutes. The supernatant was removed, and 40 mL of 0.05%
trypsin-EDTA (Lonza, Walkersville, Md) were added and incubated at
37.degree. C..+-.2.degree. C. for an additional 5-15 minutes on a
rocker. The trypsin was warmed to 37.degree. C..+-.2.degree. C. in
a water bath prior to use. After trypsin digestion, the suspension
was filtered through a 100 .mu.m cell strainer nylon filter to
remove any debris. Centrifugation at 2000 rpm for 10 minutes was
performed, and supernatant was removed. Cell pellets were
reconstituted with a volume of PlasmaLyte-A that was proportional
to the pellet size, and 20 .mu.l of the resuspended cell suspension
were mixed with 80 .mu.l of trypan blue (Sigma Aldrich, St. Louis,
Mo.) for counting. The cell count sample was placed into a
hemocytometer and evaluated using a microscope.
[0400] Chorionic membranes were digested with 25 mL of 0.75%
collagenase solution at 37.degree. C..+-.2.degree. C. for 20-40
minutes on a rocker. After collagenase digestion, the suspension
was filtered through a 100 .mu.m cell strainer nylon filter to
remove any debris. Centrifugation at 2000 rpm for 10 minutes was
performed, and supernatant was removed. Cell pellets were
reconstituted with a volume of PlasmaLyte-A that was proportional
to the pellet size, and 20 .mu.L of the resuspended cell suspension
were mixed with 80 .mu.L of trypan blue for counting. The cell
count sample was placed into a hemocytometer and evaluated using a
microscope.
[0401] Placenta membranes were analyzed prior to any processing to
determine the initial characteristics of the membranes. Table 1
contains the average cell count per cm.sup.2 and cell viability
values for the amniotic and chorionic membranes from 32 placenta
lots.
[0402] The average cell count per cm.sup.2 for the amniotic
membrane was 91,381 cells with a corresponding average cell
viability of 84.5%. For the chorionic membrane, the average cell
count per cm.sup.2 was 51,614 cells with a corresponding cell
viability of 86.0%.
[0403] These data illustrate cell numbers that are useful with
certain embodiments of the present invention; e.g. placental
product comprising an amniotic membrane containing about 10,000 to
about 360,000 cells/cm.sup.2. Since the amniotic membrane consists
of epithelial cells and stromal cells, experiments were conducted
to determine the ratio of epithelial cells to stromal cells.
Amniotic membranes from 3 placenta lots were analyzed. First, a 5
cm.times.5 cm piece of amniotic membrane was digested with
approximately 25 mL of 0.05% trypsin-EDTA (Lonza, Walkersville,
Md.) at 37.degree. C..+-.2.degree. C. in a water bath for 30
minutes. After the incubation step, epithelial cells were removed
by gently scraping the cells from the membrane. After rinsing with
PBS (Gibco Invitrogen, Grand Island, N.Y.), the membrane was
subsequently digested in the same manner as chorionic membrane
(described above). In addition, another intact 5 cm.times.5 cm
piece of amniotic membrane was digested using the standard
procedure (described above) to determine the total number of cells.
The percentage of stromal cells was then determined by dividing the
cell count from the amniotic membrane with the epithelial cells
removed with the cell count from the intact membrane.
[0404] Results indicate that 19% of the total cells were stromal
cells. Therefore, approximately 17,362 stromal cells were present
in amniotic membrane with approximately 74,019 epithelial cells.
These data indicated that there are approximately 3 times more
stromal cells in chorionic membranes as compared to amniotic
membranes. This ratio is consistent with certain embodiments of the
present invention that provide a placental product comprising a
chorionic membrane and an amniotic membrane, wherein the chorionic
membrane comprises about 2 to about 4 times more stromal cells
relative to the amniotic membrane. Table 1 Cell count per cm.sup.2
and cell viability values from fresh placental tissue from 32
donors.
TABLE-US-00001 Cell Membrane Statistics Count per cm.sup.2 Cell
Viability Amnion Average 91,381 84.5% SD 49,597 3.7% Chorion
Average 51,614 86.0% SD 25,478 4.7%
[0405] Cell count and cell viability was assessed after the
antibiotic treatment step. Table 2 provides the results from these
analyses. Cell recoveries from this step for the amniotic membrane
and the chorionic membrane were 87.7% and 70.3%, respectively.
TABLE-US-00002 TABLE 2 Cell count per cm.sup.2, cell viability, and
process (antibiotic treatm.sup.ent) cell recovery values for post
antibiotic placental tissue from 28 donors. Cell Count per Process
Cell Membrane Statistics cm.sup.2 Cell Viability Recovery Amnion
Average 75,230 84.4% 87.7% SD 46,890 4.2% 49.4% Chorion Average
33,028 85.6% 70.3% SD 18,595 4.4% 31.1%
Example 7
Development of a Placental Product Cryopreservation Procedure
[0406] Cryopreservation is a method that provides a source of
tissues and living cells. A main objective of cryopreservation is
to minimize damage to biological materials during low temperature
freezing and storage. Although general cryopreservation rules are
applicable to all cells, tissues, and organs, optimization of the
cryopreservation procedure is required for each type of biological
material. The present application discloses a cryopreservation
procedure for placental membrane products that can selectively
deplete immunogenic cells from the placental membranes; and
preserve viability of other beneficial cells that are the primary
source of factors for the promotion of healing.
[0407] During cryopreservation method development for placental
membranes, the present inventors evaluated key parameters of
cryopreservation including volume of cryopreservative solution,
effect of tissue equilibration prior to freezing, and cooling rates
for a freezing procedures.
[0408] Acceptance of tissue allografts in the absence of
immunosuppression will depend on the number of satellite immune
cells present in the tissue. Cryopreservation is an approach which
can be utilized to reduce tissue immunogenicity. This approach is
based on differential susceptibility of different cell types to
freezing injury in the presence of DMSO; leukocytes are sensitive
to fast cooling rates. The freezing rate of 1.degree. C./min is
considered optimal for cells and tissues including immune cells.
Rapid freezing rates such as 60-100.degree. C./min eliminate immune
cells. However, this type of procedure is harmful to other tissue
cells, which are desirable for preservation according to the
present invention. The developed cryopreservation procedure
utilized a cryopreservation medium containing 10% DMSO, which is a
key component protecting cells from destruction when water forms
crystals at low temperatures. The second step of cryopreservation
was full equilibration of placental membrane in the
cryopreservation medium, which was achieved by soaking membranes in
the cryopreservation medium for 30-60 min at 4.degree. C. This step
allowed DMSO to penetrate the placental tissues. Although there are
data in the literature showing that tissue equilibration prior to
freezing affects survival of immune cells (Taylor & Bank,
Cryobiology, 1988, 25:1),
[0409] It was unexpectedly found that 30-60 min placental membrane
equilibration in a DMSO-containing solution at 2-8.degree. C.
increases sensitivity of immune cells to freezing so that these
type of cells cannot withstand freezing even at a 1.degree. C./min
freezing rate.
[0410] Temperature mapping experiments were performed to analyze
the temperature profiles of potential cryopreservation conditions
for the membrane products. These results are illustrated in FIG. 1.
Eight (8) FP-90 cryobags were filled with either 20 mL or 50 mL of
cryopreservation solution, and temperature probes were placed
inside each cryobag. The first set of parameters (conditions 1
through 4 of FIG. 1a through FIG. 1d, respectively) involved a
30-minute refrigeration (2-8.degree. C.) step prior to freezing
(-80.degree. C..+-.5.degree. C.). In addition, the analysis
involved freezing of the cryobags either inside a Styrofoam
container or on the freezer shelf. The second set of parameters
(conditions 5 through 8 of FIG. 1e through FIG. 1h, respectively)
involved direct freezing (-80.degree. C..+-.5.degree. C.) of the
cryobags either inside a Styrofoam container or on the freezer
shelf. The results indicated that condition 6 and condition 2
exhibited the most gradual temperature decreases. Gradual
temperature decreases are typically desired in order to preserve
cell viability. The difference between condition 6 and condition 2
was that condition 2 included a 30-minute refrigeration step.
Therefore, the decrease in temperature from the start of freezing
to -4.degree. C., where latent heat evolution upon freezing occurs,
was examined further. For condition 6, the rate of cooling was
approximately--1.degree. C./minute during this period. The rate of
cooling for condition 2 was approximately--0.4.degree. C./minute
during the same timeframe. Therefore, condition 2 was selected for
incorporation into a non-limiting cryopreservation process since
slower rates of cooling are generally desired to maintain optimal
cell viability.
[0411] FIG. 2 depicts the effects of cryopreservation solution
volume on process (cryopreservation) cell recovery for the amniotic
membrane. The analysis of the 10 mL cryopreservation solution
volume involved 5 placenta lots, and the analysis of the 20 mL
cryopreservation solution volume included 3 lots. For the 50 mL
cryopreservation solution volume, 14 placenta lots were
analyzed.
[0412] As depicted in FIG. 2, the 50mL volume of cryopreservation
solution volume provided superior cell recovery compared to that of
the 10 ml and 20 ml. These data indicate that a cryopreservation
medium volume of greater than 20mL such as about 50 mL or more can
provide superior placental product according to the present
invention.
[0413] FIG. 3 shows the results of a similar study of analysis of
the cryopreservation cell recovery for the chorionic membrane,
demonstrating that a cryopreservation solution volume of 50 mL was
optimal. The analysis of the 10 mL cryopreservation solution volume
involved 5 placenta lots, and the analysis of the 20 mL
cryopreservation solution volume included 3 lots. For the 50 mL
cryopreservation solution volume, 16 placenta lots were
analyzed.
[0414] Experiments were conducted to evaluate different potential
freezing conditions to maximize cell recovery after the
cryopreservation process. FIG. 4 (cells from amniotic membrane) and
FIG. 5 (cells from chorionic membranes) depict these results,
showing the effects of refrigeration time and freezing parameters
on process (cryopreservation) cell recovery for the chorionic
membrane. Three conditions were analyzed. These conditions were
also linked to the temperature mapping studies. The first condition
involved directly freezing the product unit on a shelf within the
freezer (-80.degree. C..+-.5.degree. C.). The second condition also
contained a direct freeze, but the product unit was placed into a
Styrofoam container within the freezer. The third condition
included a refrigeration (2-8.degree. C.) period of 30 minutes
prior to the freezing step. For the amniotic membrane, 3 placenta
lots were evaluated. Two (2) placenta lots were analyzed for the
chorionic membrane. Results indicated that the third condition was
optimal for both membrane types.
[0415] All of the cryopreservation parameters that were assessed
for the amniotic and chorionic membranes are summarized in Table 3
and Table 4. The evaluation of the cell recoveries and cell
viabilities from these experiments resulted in the selection of the
final parameters for the manufacturing process. In addition, all
average cell viability values were 70%.
TABLE-US-00003 TABLE 3 Post thaw cell count per cm.sup.2, cell
viability, and process (cryopreservation) cell recovery values for
the amniotic membrane. Cell Process Condition Count Cell Cell
Comments/ Parameter Tested Statistics per cm.sup.2 Viability
Recovery Conclusions Refrigerate All Average 55,709 83.4% 64.2%
Overall at 2-8.degree. C. for conditions SD 45,210 4.4% 22.5%
assessment. 30-60 min N 32 32 32 and freeze at -80.degree. C. .+-.
10.degree. C. Refrigeration 30 min Average 52,173 83.1% 63.7% No
significant time interval SD 39,750 4.5% 21.4% difference N 26 26
26 found in 60 min Average 71,033 85.0% 66.5% process cell SD
66,525 3.9% 29.3% recovery. A N 6 6 6 30-60 min range was
established. Thawing 37.degree. C. .+-. Average 48,524 83.3% 64.0%
No significant temperature 2.degree. C. water SD 27,804 1.7% 34.4%
difference bath N 7 7 7 found in Room Average 57,721 83.5% 64.3%
process cell temp SD 49,271 4.9% 19.0% recovery. The water bath N
25 25 25 room temp condition was selected for logistical reasons.
Holding 1-15 min Average 50,873 83.1% 65.0% No significant period
after SD 38,969 3.9% 24.2% difference transfer into N 26 26 26
found in saline 1 hr Average 76,667 85.1% 61.0% process cell SD
66,565 6.2% 14.3% recovery. N 6 6 6 Membranes can be held in saline
for up to 1 hr. Tissue size 5 cm .times. 5 Average 58,431 83.3%
62.8% No decrease cm SD 47,603 4.5% 21.7% in process cell N 28 28
28 recovery from 2 cm .times. 2 Average 36,656 84.4% 73.9% the 5 cm
.times. 5 cm SD 13,175 3.4% 29.5% cm product to N 4 4 4 the 2 cm
.times. 2 cm product. Both sizes were acceptable for use.
TABLE-US-00004 TABLE 4 Post thaw cell count per cm.sup.2, cell
viability, and process (cryopreservation) cell recovery values for
the chorionic membrane. Cell Process Condition Count Cell Cell
Parameter Tested Statistics per cm.sup.2 Viability Recovery
Refrigerate All Average 23,217 87.3% 102.8% at 2-8.degree. C. for
conditions SD 9,155 4.1% 65.5% 30-60 min N 27 27 27 and freeze at
-80.degree. C. .+-. 10.degree. C. Dispase 30 min Average 22,354
85.7% 81.1% No decrease treatment SD 9,505 5.1% 32.4% in process
cell N 24 24 24 recovery for 45 min Average 27,125 90.6% 172.6% the
45 min SD 7,963 2.2% 101.2% treatment. A N 6 6 6 30-45 min range
was established. Refrigeration 30 min Average 23,815 86.8% 102.2%
The process time interval SD 9,681 5.2% 68.8% recovery value N 25
25 25 was >80% for 60 min Average 20,773 85.8% 84.9% the 60 min
SD 7,356 4.7% 14.4% time interval. N 5 5 5 A 30-60 min range was
established. Thawing 37.degree. C. .+-. Average 33,360 85.9% 114.7%
No significant temperature 2.degree. C. water SD 8,497 4.0% 38.1%
difference bath N 5 5 5 found in Room Average 21,298 86.8% 96.3%
process cell temp SD 8,189 5.3% 67.2% recovery. The water bath N 25
25 25 room temp condition was selected for logistical reasons.
Holding 1-15 min Average 23,733 86.6% 100.6% No significant period
after SD 9,674 5.1% 67.0% difference transfer into N 26 26 26 found
in saline 1 hr Average 20,550 87.0% 91.4% process cell SD 6,575
4.8% 32.0% recovery. N 4 4 4 Membranes can be held in saline for up
to 1 hr. Tissue size 5 cm .times. 5 Average 23,391 86.1% 99.6% No
decrease cm SD 8,865 5.0% 58.7% in process cell N 23 23 23 recovery
from 2 cm .times. 2 Average 23,036 88.4% 98.7% the 5 cm .times. 5
cm SD 11,362 5.0% 81.3% cm product to N 7 7 7 the 2 cm .times. 2 cm
product. Both sizes were acceptable for use. Notes: cm =
centimeter; min = minutes; temp = temperature; hr = hour, SD =
standard deviation; N = number.
[0416] These data are consistent with certain embodiments of the
present invention that provide a placental product comprising an
amniotic membrane containing about 40,000 to about90,000 or to
about 260,000 cells/cm.sup.2.
Example 8
Qualitative Evaluation of Cell Viability by Tissue Staining
[0417] The amniotic and chorionic membranes were stained using a
LIVE/DEAD.RTM. Viability/Cytotoxicity kit (Molecular Probes Inc.,
Eugene, Oreg.) to qualitatively assess cell viability. Staining was
performed as per the manufacturer's protocol. Membrane segments of
approximately 0.5 cm.times.0.5 cm were used. Evaluation of stained
membranes was performed using a fluorescent microscope. An intense
uniform green fluorescence indicated the presence of live cells,
and a bright red fluorescence indicated the presence of dead cells.
Images of fresh amniotic and chorionic membranes as well as
cryopreserved amniotic and chorionic membranes demonstrated that
the manufacturing process did not alter the phenotypic
characteristics of the membranes post thaw.
[0418] FIG. 6 contains representative images of fresh amniotic and
chorionic membranes as well as cryopreserved amniotic and chorionic
membranes. These images demonstrated that the manufacturing process
did not alter the phenotypic characteristics of the membranes and
the proportion of viable cell types (epithelial and stromal cells)
in the membranes post thaw.
[0419] FIG. 6. Representative images of the live/dead staining of
the epithelial layer of fresh amniotic membrane (A); epithelial
layer of cryopreserved amniotic membrane (B); stromal layer of
fresh amniotic membrane (C); stromal layer of cryopreserved
amniotic membrane (D); fresh chorionic membrane (E); and
cryopreserved chorionic membrane (F). Live cells are green, and
dead cells are red.
Example 9
Placental Tissue Immunogenicity Testing
[0420] One unique feature of the human amnion and chorion is the
absence of fetal blood vessels that prevent mobilization of
leukocytes from fetal circulation. On the fetal side, macrophages
resident in the chorioamniotic mesodermal layer represent the only
population of immune cells. Thus, fetal macrophages present in the
chorion and amnion are the major source of tissue immunogenicity.
However, the number of macrophages in amnion is significantly lower
(Magatti et al, Stem Cells, 2008, 26: 182), and this explains the
low immunogenicity of amnion and the ability to use it across HLA
barriers without matching between the donor and recipient (Akle et
al, Lancet, 1981, 8254:1003; Ucakhan et al., Cornea, 2002, 21:169).
In contrast, the chorion is considered immunogenic. In a study
where the amnion was used together with the chorion for plastic
repair of conjunctival defects, the success rate was low (De Roth
Arch Ophthalmol, 1940, 23: 522). Without being bound by theory, the
present inventors believe that removal of CD14+ cells from
placental membranes eliminates activation of lymphocytes in vitro.
In addition to the presence of fetal macrophages, the present
inventors believe that immunogenicity of chorion can be mediated by
contamination of blood cells coming from the maternal trophoblast,
which contains blood vessels. Thus, the processing of placental
membrane for clinical use can be enhanced by purification of the
amnion and chorion from maternal trophoblasts and selective
elimination of all CD14+ fetal macrophages.
[0421] Immunogenicity testing can be used to characterize a
placental product as safe clinical therapeutics. For example, two
bioassays can be used to test immunogenicity of manufactured
placental products: Mixed Lymphocyte Reaction (MLR) and
Lipopolysaccharide (LPS)-induced Tumor Necrosis Factor
(TNF)-.alpha. secretion.
Example 10
Mixed Lymphocyte Reaction (MLR)
[0422] An MLR is a widely used in vitro assay to test cell and
tissue immunogenicity. The assay is based on the ability of immune
cells (responders) derived from one individual to recognize
allogeneic Human Leukocyte Antigen (HLA) and other antigenic
molecules expressed on the surface of allogeneic cells and tissues
(stimulators) derived from another individual when mixed together
in a well of an experimental tissue culture plate. The response of
immune cells to stimulation by allogeneic cells and tissues can be
measured using a variety of methods such as secretion of particular
cytokines (e.g., Interleukin (IL)-2), expression of certain
receptors (e.g., IL-2R), or cell proliferation, all of which are
characteristics of activated immune cells.
[0423] Placental tissue samples representing different steps of the
presently disclosed manufacturing process were used for
immunogenicity testing. These samples included amnion with chorion
and trophoblast as a starting material and separated
choriotrophoblast, chorion, trophoblast, and amnion. Both freshly
purified and cryopreserved (final products) tissues were
tested.
[0424] For the MLR assay, cells from placental tissues were
isolated using 280 U/mL of collagenase type II (Worthington, Cat
No. 4202). Tissues were treated with enzyme for 60-90 min at
37.degree. C..+-.2.degree. C., and the resulting cell suspension
was filtered through a 100 .mu.m filter to remove tissue debris.
Single cell suspensions were then centrifuged using a Beckman, TJ-6
at 2000 rpm for 10 min and washed twice with DPBS. Supernatant was
discarded after each wash, and cells were resuspended in 2 mL of
DMEM (Invitrogen, Cat No. 11885) and evaluated for cell number and
cell viability by counting cells in the presence of Trypan blue dye
(Invitrogen, Cat No. 15250-061). For the MLR, placental-derived
cells were mixed with allogeneic hPBMCs at a 1:5 ratio in 24-well
culture plates in DMEM supplemented with 5% fetal bovine serum
(FBS) and incubated for 4 days in the incubator containing 5%
CO.sub.2, 95% humidity at 37.degree. C..+-.2.degree. C. Human
Peripheral Blood Mononuclear Cells (hPBMCs) alone were used as a
negative control, and a mixture of two sets of hPBMCs derived from
two different donors was used as a positive MLR control. After 4
days of incubation, cells were collected from wells, lysed using a
lysis buffer (Sigma, Cat No. C2978) supplemented with protease
inhibitor cocktail (Roche, Cat No. 11836153001), and IL-2R was
measured in cell lysates using the sIL-2R ELISA kit (R&D
Systems, Cat No. SR2A00) according to the established protocol
(G-SOP-Q088).
[0425] The level of IL-2R is a measure of activation of T-cells in
response to immunogenic molecules expressed by allogeneic cells.
Results of 2 out of 12 representative experiments are shown in FIG.
7 and FIG. 8. Results presented in these figures demonstrate a
method of manufacture of placental membranes, resulting in low
immunogenicity of the final products.
[0426] As depicted in FIG. 7: the manufacturing process serially
reduces immunogenicity of the placental product. Samples
representing different steps of the manufacturing process
(Chorion+Trophoblast (CT), Trophoblast (T), Amnion (AM), and
Chorion (CM)) were co-cultured with hPBMCs for 4 days. IL-2.alpha.R
was measured in cell lysates as a marker of T-cell activation.
Negative control shows a basal level of immune cell activation:
PBMCs derived from one donor were cultured alone. Positive control:
a mixture of PBMCs derived from 2 different donors.
[0427] As depicted in FIG. 8, selective depletion of immunogenicity
results from the present cryopreservation process of producing the
present placental products, as evidenced by the significant
decrease in immunogenicity upon cryopreservation.
Example 11
LPS-Induced TNF-.alpha. Secretion by Placental Membrane Cells
[0428] As described herein, fetal macrophages present in the amnion
and chorion are a major source of tissue immunogenicity. Without
being bound by theory, the present inventors believe that removal
of CD14+ cells from placental membrane eliminates activation of
lymphocytes and that depletion of allogeneic donor tissue
macrophages decreases the level of inflammatory cytokine secretion
and tissue immunogenicity. The inventors also believe that
reduction of tissue immunogenicity can also be reached by depletion
of TNF-.alpha. with anti-TNF-.alpha. antibodies or suppression of
TNF-.alpha. secretion by IL-10. Macrophages in fetal placental
membranes respond to bacteria by secretion of inflammatory
cytokines. The secretion of TNF-.alpha. by fresh placental
membranes in vitro in response to bacterial LPS is significantly
higher in the chorionic membrane. Thus, the present inventors
believe that immunogenicity of placental membranes is mediated by
macrophages, the amount and/or activity of which is higher in the
chorionic membrane.
[0429] According to the present invention, selective depletion of
macrophages is an approach to selectively deplete immunogenicity of
the amniotic and chorionic membranes, allowing the use of both
allogeneic membranes for clinical applications. The assay of
functional macrophages in a placental product is used here as an
assay for immunogenicity testing (e.g. in production or prior to
clinical use) based on the facts that: macrophages are the source
of immunogenicity in chorionic membranes. Macrophages in
placenta-derived membranes respond to bacterial LPS by secretion of
high levels of TNF-.alpha.; and TNF-.alpha.0 is a critical cytokine
involved in immune response and allograft tissue rejection.
Therefore, secretion of TNF-.alpha. by placenta-derived membranes
in response to LPS is used here to characterize tissue
immunogenicity and for pre-use screening.
Example 12
Establishment of Allowed LPS-Induced TNF-.alpha. Secretion Level by
Placental Membranes
[0430] Data from published reports regarding the level of
TNF-.alpha., which is associated with the absence or an
insignificant immune response in a variety of experimental systems,
are presented in Table 5. These data indicate that a TNF-.alpha.
level below 100 pg/mL correlates with a low immune response. The
ability of amniotic and chorionic membranes to produce TNF-.alpha.
spontaneously and in response to bacteria or bacterial LPS in vitro
has been shown by a number of investigators. Table 6 summarizes
such data. The lowest spontaneous TNF-.alpha. secretion by amniotic
membrane of about 70 pg/cm.sup.2 of the membrane was reported by
Fortunato et al. All reports also showed that fresh placental
membranes secrete large amounts of TNF-.alpha. in response to
bacteria or bacterial LPS, which is attributed to the presence of
viable functional macrophages.
TABLE-US-00005 TABLE 5 TNF-.alpha. levels associated with no or an
insignificant immune response. TNF-.alpha. levels associated with
the Description of absence/reduction experimental system of immune
response Comments References IL-10-induced inhibition Mean 260
pg/mL Wang et al., of MLR in vitro. Transplantation, TNF was
measured in 2002, 74: 772 tissue culture supernatant by ELISA. MLR
using skin tissue Mean 100 pg/mL explants (0.02 cm2 per well) as
stimulators in the presence or absence of IL-10 (skin explant
assay). Skin tissue destruction was assessed microscopically, and
severity was assigned based on histopathological tissue damage.
Endogeneous TNF ~0.04 U/mL for the TNF activity Shalaby et al, J
production in MLR in the negative control and per mg is not
Immunol, 1988, presence or absence of MLR in the presence provided.
141: 499 anti-TNF antibodies. TNF of anti-TNF levels were assessed
antibodies, which using the WEHI-164 correlated with no or
cytotoxicity assay. significant inhibition of lymphocyte
proliferation TNF levels in BAL fluid of Isograft: below Unmodified
Sekine et al, J lung isografts, unmodified detection; allograft:
~45 pg/mL Immunol, 1997, allograft, and alveolar AM-depleted
allograft: (immunogenic) 159: 4084. macrophages (AM) ~15 pg/mL of
BAL depleted allograft in rats. (total 75 pg/5 ml of BAL) TNF
levels in MLR after ~<200 pg/mL TNF Ohashi et al, 48 hours in
the presence correlated with a Clin Immunol, or absence of advanced
complete inhibition of 2009, e-pub glycation end products MLR ahead
of print (MLR inhibitors). TNF levels in MLR. <100 pg/mL TNF in
Toungouz et al, MLR with HLA- Hum Immunol, matched donors 1993, 38:
221 (control, no stimulation) TNF activity in MLR when Negative
control ~20 Unit of activity Lomas et al, pieces of cryopreserved U
of TNF activity; was calculated Cell Tissue skin allografts (~0.2
cm.sup.2) MLR with skin as TNF in Bank, 2004, 5: were incubated
with explants - 0-40 U; ng/mL divided 23. hPBMCs for 24 hours.
Positive control - 600 U by OD at 570 nm Positive control: for the
hPBMC + LPS; negative - same hPBMC alone. experimental well
Cytokine time course in Optimal TNF Jordan & Ritter, MLR,
including TNF. after 24 hours - J Immunol ~150 pg/mL Meth, 2002,
260: 1 MLR using skin tissue For no skin Recalculation Dickinson et
al, explants (0.02 cm.sup.2 per destruction: 0.5-1.1 pg/mL per 1
cm.sup.2 of Cytokine, 1994, well) as stimulators in the for HLA
skin tissue: 6: 141 presence or absence of compatible lowest TNF
anti-TNF antibodies (skin responders, and 2.6-1376 pg/mL non-
explant assay). Skin for immunogenic tissue destruction was
unmatched MLR level is 100 pg/cm.sup.2 assessed microscopically,
and severity was assigned based on histopathological tissue
damage.
TABLE-US-00006 TABLE 6 Secretion of TNF in vitro by fresh amniotic
and chorionic membranes. TNF levels Comments/ secreted by fresh
recalculations placental of the lowest Description of membranes in
TNF levels per experimental system culture cm.sup.2 References TNF
secretion by Chorion: basal Lowest TNF Zaga et al., Biol "fresh"
amnion and 3.3 .+-. 0.46 ng/cm.sup.2, level for amnion Reprod,
2004, chorion tissues (1.44 cm2) LPS-induced - 150-250 ng/cm.sup.2
is 1200 pg/cm.sup.2 71: 1296 incubated for 24 Amnion: basal hours
in the presence 2.5 .+-. 1.3 ng/cm.sup.2, or absence of LPS
LPS-induced - ~50 ng/cm.sup.2 (500 ng/mL). TNF secretion by Basal
~1-2.5 pg/.mu.g Lowest TNF Zaga-Clavellina "fresh" amnion and total
protein in the level for amnion et al, Reprod chorion tissues (1.8
cm medium for both is 800 pg/cm.sup.2 Biol Endocrinol, diameter
disks: 2.5 cm.sup.2) amnion and 2007, 5: 46 incubated for 24
chorion; hours in the presence E. Coli-induced: or absence of E.
Coli amnion - 29.2 in 1 mL medium. (14.5-35.3) pg and chorion -
53.15 (40-94.2) pg per .mu.g total protein TNF secretion by Basal:
~2-64 U/mL 1 unit = ~100-200 pg/mL; Paradowska et "fresh" amnion
and or 8-10 mg chorion; Lowest TNF al, Placenta, chorion tissues
<1 U/mL for 5-7 mg level for amnion 1997, 18: 441 (chorion 8-10
mg amnion. is <100 pg/mL tissue/mL; amnion 5-7 mg/mL,
LPS-induced: >100 corresponding to 0.02-0.04 cm.sup.2) U/10 mg
for chorion <2500 pg/cm.sup.2 incubated for 20 hours and ~15-17
U/10 mg in the presence or for amnion absence of LPS (5 .mu.g/mL).
TNF secretion by Amnion: Basal - 40 pg/mL, Lowest TNF Fortunato et
al, "fresh" amnion (0.57 cm.sup.2) LPS-induced - 410 pg/mL level
for fresh Am J Obstet in 0.8 mL amnion is ~70 pg/cm.sup.2 Gynecol,
1996, incubated for 24 hours 174: 1855 in the presence or absence
of LPS (50 ng/mL). TNF secretion by Basal: Amnion ~7-13 ng/mL/g
Amnion is 5-7 mg Thiex et al, "fresh" amnion and tissue);
corresponds Reprod Biol chorion tissues (4 cm.sup.2) Chorion ~18
ng/mL/g ~0.02-0.04 cm.sup.2; Endocrinol, incubated for 24 tissue 1
g is ~6 cm.sup.2; 2009, 7: 117 hours in the presence LPS-induced
(1000 ng/mL): Lowest TNF or absence of LPS (1-1000 ng/mL) Amnion
level for amnion ~14 ng/mL/g), is ~1000 pg/cm.sup.2 Chorion ~27
ng/mL/g
Example 13
LPS-Induced TNF-.alpha. Secretion and CT induced MLR Immunogenicity
Assay
[0431] 2 cm.times.2 cm pieces of placental membranes representing
intermediates and final products were placed in tissue culture
medium and exposed to bacterial LPS (1 .mu.g/mL) for 20-24 hr.
After 24 hours, tissue culture supernatant were collected and
tested for the presence of TNF-.alpha. using a TNF-.alpha. ELISA
kit (R&D Systems) according to the manufacturer's protocol.
Human hPBMCs (SeraCare) known to contain monocytes responding to
LPS by secretion of high levels of TNF-.alpha. were used as a
positive control in the assay. hPBMCs and placental tissues without
LPS were also included as controls in the analysis. In this assay,
TNF detected in the culture medium from greater than 70
.mu.g/cm.sup.2 (corresponding to 280 pg/mL) for both spontaneous
and LPS-induced TNF-.alpha. secretion was considered
immunogenic.
[0432] As depicted in FIG. 9A and FIG. 9B, the manufacturing
process serially reduces immunogenicity of the placental product.
Samples representing different steps of the manufacturing process
(Amnion+Chorion+Trophoblast (ACT), Chorion+Trophoblast (CT), Amnion
(AM), and Chorion (CM)) were incubated in the presence of LPS for
24 hr, and after that tissue culture supernatants were tested for
the TNF-.alpha. by ELISA. Tissues cultured in medium without LPS
show the basal level of TNF a secretion. PBMCs, which are known to
secrete high levels of TNF, were used as a positive control.
[0433] The low levels of TNF-.alpha. and the absence of the
response to LPS by AM and CM indicates the absence of viable
functional macrophages that are the major source of immunogenicity
for amniotic and chorionic membranes. Results of this assay showed
a correlation with the MLR data: tissues that produce high levels
of TNF-.alpha. in response to LPS are immunogenic in the MLR assay
(FIG. 9A and FIG. 9B, for TNF-.alpha. secretion; FIG. 9,
C-MLR).
[0434] As depicted in FIG. 9A and FIG. 9B, the manufacturing
process serially reduces immunogenicity of the placental product.
Samples representing different steps of the manufacturing process
(Amnion+Chorion+Trophoblast (ACT), Chorion+Trophoblast (CT), Amnion
(AM), and Chorion (CM)) were incubated in the presence of LPS for
24 hr, and after that tissue culture supernatants were tested for
the TNF-.alpha. by ELISA. Tissues cultured in medium without LPS
show the basal level of TNF a secretion. PBMCs, which are known to
secrete high levels of TNF, were used as a positive control.
[0435] Choriotrophoblast (CT), which secreted high levels of
TNF-.alpha. (FIG. 9, B), was tested in MLR against two different
PBMC donors. CT cells were co-cultured with PBMCs for 4 days.
IL-2.alpha.R was measured in cell lysates as a marker of T-cell
activation. Positive control: a mixture of PBMCs derived from 2
different donors.
[0436] FIG. 9C shows that preparations producing high levels of
TNF-.alpha. are immunogenic. Choriotrophoblast (CT), which secreted
high levels of TNF-.alpha. (FIG. 9 B), was tested in MLR against
two different PBMC donors. CT cells were co-cultured with PBMCs for
4 days. IL-2.alpha.R was measured in cell lysates as a marker of
T-cell activation. Positive control: a mixture of PBMCs derived
from 2 different donors.
Example 14
Analysis of Placental Cells by FACS
[0437] Knowing the cellular composition of amnion and chorionic
membranes is important for developing a thorough understanding of
potential functional roles in wound healing and immunogenicity.
Previous reports demonstrated that both amnion and chorion contains
multiple cell types. Purified amnion has two major cellular layers:
epithelial cells and stromal. In addition to epithelial cells and
fibroblasts, stromal cells were identified in the amnion and
chorion. Although there are no fetal blood vessels within either
the amniotic or chorionic membranes, both membranes comprise
resident fetal macrophages. The close proximity to maternal blood
circulation and decidua provide a potential source of immunogenic
cells (maternal leukocytes and trophoblast cells) and therefore are
a potential source of immunogenicity. To investigate the cellular
composition of the amnion and chorion, FACS analysis was
performed.
Example 14.1
FACS Procedure: Single Cell Suspension Preparation
[0438] Purified amnion and chorionic membranes were used for
cellular phenotypic analysis via FACS. Cells from amnion and
chorion were isolated using 280 U/mL collagenase type II
(Worthington, Cat No. 4202). Tissues were treated with enzyme for
60-90 min at 37.degree. C..+-.2.degree. C., and the resulting cell
suspension was filtered through a 100 .mu.m filter to remove tissue
debris. Single cell suspensions were then centrifuged using a
Beckman TJ-6 at 2000 rpm for 10 min and washed twice with DPBS.
Supernatant was discarded after each wash, and cells were
resuspended in 2 mL of FACS staining buffer (DPBS+0.09%
NaN.sub.3+1% FBS).
Example 14.2
Immunolabeling Cells for Specific Cellular Markers
[0439] Once the single cell suspension was prepared according to
Example 10, a minimum of 1.times.10.sup.5 cells in 100 .mu.L of
FACS staining buffer was treated with antibodies labeled with
fluorescent dye. Table 7 provides descriptions of the antibodies
and the amounts used. For cell surface markers, cells were
incubated for 30 min at room temperature in the dark with
antibodies followed by washing twice with FACS staining buffer by
centrifugation at 1300 rpm for 5 min using a Beckman TJ-6
centrifuge. Cells were then resuspended in 400 .mu.L of FACS
staining buffer and analyzed using a BD FACSCalibur flow cytometer.
To assess cell viability, 10 .mu.L of 7-AAD regent (BD, Cat No.
559925) was added just after the initial FACS analysis and analyzed
again. For intracellular staining, cells were permeabilized and
labeled following the manufacturer's recommendations (BD
Cytofix/Cytoperm, Cat No. 554714) and analyzed using a BD
FACSCalibur flow cytometer.
TABLE-US-00007 TABLE 7 Description of reagents used for placental
cell characterization by FACS. Volume of Cell marker antibody
antibody and solution Cell marker Cell marker label type Cat No.
used type specificity IgG1 BD 559320 5 .mu.L Cell surface Isotype
control isotype- PE CD105-PE Caltag 20 .mu.L Cell surface MSC
marker MHCD10504 CD166-PE BD 559263 80 .mu.L Cell surface MSC
marker CD45-PE BD 555483 10 .mu.L Cell surface Hematopoetic cell
marker IgG2a BD 555574 2 .mu.L Cell surface Isotype control
isotype- PE CD14-PE BD 555398 20 .mu.L Cell surface Monocyte marker
HLA-DR-PE BD 556644 20 .mu.L Cell surface HLA class II specific for
antigen- presenting cells IgG1 BD555748 5 .mu.L Cell surface
Isotype control isotype- FITC CD86-FITC BD 557343 20 .mu.L Cell
surface Immune co- stimulatory marker CD40-FITC BD 556624 20 .mu.L
Cell surface Immune co- stimulatory marker IgG1 Dako X0931 10 .mu.L
Intracellular Isotype control isotype- unlabeled Cytokeratin Dako
M7018 2 .mu.L Intracellular Trophoblast 7-unlabeled marker Rabbit
anti- Dako F0261 5 .mu.L Intracellular Secondary mouse FITC
antibody
Example 15
Phenotypic Analysis of Placental Cells
[0440] FACS analysis of single cell suspensions of both amnion and
chorion membranes demonstrates that both membranes contain cells
expressing markers specific for mesenchymal stem cells (refer to
Table 8), implicating the presence of MSCs. In addition, several
immunogenic markers, which are more likely expressed on CD14+
placental macrophages, were detected. The % ranges for different
markers are wide. It can be explained by: 1) high variability in
cell number between placenta donors; and 2) technical issues, which
include the presence of high and variable cellular and tissue
debris in the cellular suspension. Although debris can be gated
out, debris particles that are comparable with cells by size will
affect the accuracy of the calculated % for each tested marker. In
addition, Table 9 provides a FACS analysis of cells isolated from
the amniotic and chorionic membranes that were cultured in 10% FBS
in DMEM at 37.degree. C..+-.2.degree. C. until confluency (passage
0 cells).
[0441] These data demonstrated that cells derived from amniotic and
chorionic membranes retained a phenotype similar to MSCs after
culturing. In conclusion, the presence of stromal cells in
placental tissues was confirmed by FACS analysis.
[0442] These data are consistent with certain embodiments of the
present invention that provide a placental product comprising an
amniotic membrane containing MSCs.
TABLE-US-00008 TABLE 8 Characterization of the cellular composition
of placental membranes based on selective CD markers. Amnion (%
Chorion (% Marker range) range) MSC Markers CD105 72.1-88.2
6.4-78.5 CD166 17.3-58.0 4.8-51.5 Hematopoietic Cell CD14 6.93-10.5
0.9-6.1 Markers CD45 4.4-9.9 4.6-14.7 Immune co-stimulatory HLA-DR
0-5.6 0-14.7 markers CD86 24.3-49.6 4.9-22.5 CD40 7.0-68.7 2-5.8
Trophoblast marker Cytokeratin-7 1.36-4.66 2.71-23.07
TABLE-US-00009 TABLE 9 FACS analysis of cultured cells (passage 0)
from placenta lot D16. Cell Surface Marker Amnion (%) Chorion (%)
CD45 2.18 0.53 CD166 92.77 82.62 CD105 83.02 86.73 CD49a 92.28
92.26 CD73 89.57 94.57 CD41a -0.03 -0.05 CD34 -0.23 -0.25 HLA-DR
-0.23 -0.19 CD19 -0.19 -0.22 CD14 -0.25 -0.27 CD90 99.12 98.00
Example 16
Aherence of Cells Derived from Placental Products.
[0443] Therapeutic cells, in optional embodiment of the present
invention, are adherent, express specific cellular markers such as
CD105 and lack expression of other markers such as CD45, and
demonstrate the ability to differentiate into adipocytes,
osteoblasts, and
[0444] The expression of specific cellular markers has already been
described in Example 15. To determine if the cells within the
placental product derived from the chorionic membrane can adhere to
plastic and differentiate into one of the lineages, cells were
isolated from the placental product derived from the amnion as
described in this invention and cultured at 37.degree.
C..+-.2.degree. C. and expanded.
[0445] FIG. 10 shows representative images of cells isolated and
cultured from amniotic (FIG. 10.A) and chorionic (FIG. 10.B)
membranes demonstrating plastic adherence, which is a key feature
of MSCs. As a comparison, a representative image of MSCs isolated
and expanded from human bone marrow aspirate is also provided (FIG.
10.C). Together, these data show that cells derived from amniotic
and chorionic membranes retain a phenotype similar to MSCs after
culturing as demonstrated by the cellular markers present in
addition to the ability of the cells to adhere to plastic. In
conclusion, the presence of MSCs in placental tissues was confirmed
by FACS analysis and tissue culture
Example 17
Live CD45+ FACS Analysis
[0446] As CD45 is a general marker for hematopoietic cells and
therefore a marker for the presence immunogenic cells, the presence
of CD45+ cells may correlate well with how immunogenic a tissue may
be. An initial study indeed showed a correlation between amount of
immunogenicity as measured via an in vitro MLR assay of placental
tissue at various stages within the manufacturing process (as
described previously), and the amount of CD45+ cells was determined
via FACS analysis. As FIG. 11 demonstrates, membranes that trigger
the expression of high levels of IL-2sR on hPBMC responders in MLR
also contained a high percentage of CD45+ cells, indicating that
immunogenicity of placental membranes can be correlated with the
number of CD45+ cells. Further studies revealed, however, that
quantifying CD45+ cells via FACS alone showed high variability that
did not allow for the establishment of a safety threshold for CD45+
cells in placental membranes. Accordingly, the inventors evaluated
whether or not viability of CD45+ cells is correlated with
immunogenicity.
[0447] To eliminate some of the variability in CD45+ measurements
via FACS, viability of CD45+ cells was assessed, as dead CD45+
cells do not contribute to immunogenicity. To ensure an accurate
assessment of live CD45+ cells, a pilot experiment was conducted in
which a single cell suspension of amnion membrane was spiked in
with a known concentration of live CD45+ cells (hPBMCs) ranging
from a theoretical 1.25% to 20% (0.75-12%--actual % of the spiked
cells) of the total cell concentration in suspension. Cells were
stained with CD45-PE antibody at determined concentrations (refer
to Table 10), incubated with 7-AAD cell viability test reagent, and
analyzed using a BD FACSCalibur. Table 10 demonstrates that
recovery of known amounts of CD45+ cells was not correct (4th
column in the table). For example, although 12% of PBMCs was spiked
into a single-cell suspension of amnion membrane, only 4.26% of
CD45+ cells were recovered according to FACS analysis (>60%
difference from the actual spike). To correlate with
immunogenicity, MLR was also performed in parallel. Briefly, single
cell suspensions of amniotic membrane spiked with various amounts
of live hPBMCs were co-cultured with another donor of PBMCs in the
MLR. FIG. 12 depicts a correlation between the amount of CD45+
cells present in amnion-derived cell suspensions and immunogenicity
in MLR in vitro. Table 10 and FIG. 12 show that the suspensions
spiked with higher amounts of live CD45+ cells resulted in higher
immunogenicity as measured by IL-2sR expression on the hPBMC
responder donor.
TABLE-US-00010 TABLE 10 % CD45+ recovery experiments. Cell
suspension Sample immunogenicity Description % CD45+ Actual spike
(tested in MLR (in % of cell cells (%, based on 60% and expressed
types in the (detected CD45+ cells in this % Difference as IL-2R in
mixture) by FACS) hPBMC batch) from actual spike pg/mL) 100% amnion
0.65 N/A N/A 20.23 0% PBMC N/A N/A N/A 15.6 (negative control) 100%
PBMC 61.51 N/A N/A 86.31 (positive control) 20% PBMC + 4.26 12
64.5% 24.38 80% Amnion 10% PBMC + 2.24 6 62.7% 21.17 90% Amnion 5%
PBMC + 1.7 3 43.3% 16.75 95% Amnion 2.5% PBMC + 1.36 1.5 Not 15.9
97.5% calculated* Amnion 1.25% PBMC + 1.06 0.75 Not 12.27 98.75%
calculated* Amnion Notes: N/A--not applicable; *Not calculated -
values are close to the method detection limits
Example 18
Protein Array Analyses
[0448] The protein profiles of amniotic and chorionic membranes
were investigated using a SearchLight Multiplex chemiluminescent
array. The presence of proteins in tissue membrane extracts and
secreted by tissues in culture medium was investigated. For
comparison, two commercially available products containing living
cells, Apligraf and Dermagraft, were assayed.
Example 18.1.
Dermagraft
[0449] Dermagraft membrane was thawed and washed according to the
manufacturer's instructions. Dermagraft membrane was cut into 7.5
cm.sup.2 pieces. For tissue lysates, one 7.5 cm.sup.2 piece of
membrane was snap frozen in liquid nitrogen followed by
pulverization using a mortar and pestle. Crushed tissue was
transferred to a 1.5 mL microcentrifuge tube and 500 .mu.L of Lysis
buffer (Cell Signaling Technologies, Cat No. 9803) with protease
inhibitor (Roche, Cat No. 11836153001) was added and incubated on
ice for 30 min with frequent vortexing. The sample was then
centrifuged at 16000 g for 10 min. The supernatant was collected
and sent for protein array analysis by Aushon Biosystems. For
tissue culture, one 7.5 cm.sup.2 piece of membrane was plated onto
a well of a 12-well dish and 2 mL of DMEM+1% HSA+
antibiotic/antimycotic were added and incubated at 37.degree.
C..+-.2.degree. C. for 3, 7, or 14 days. After incubation, tissue
and culture media were transferred to a 15 mL conical tube and
centrifuged at 2000 rpm for 5 min. Culture supernatant was
collected and sent for protein array analysis by Aushon
Biosystems.
Example 18.2
Apligraf
[0450] Apligraf membrane was cut into 7.3 cm.sup.2 pieces. For
tissue lysates, one 7.3 cm.sup.2 piece of membrane was snap frozen
in liquid nitrogen followed by pulverization using a mortar and
pestle. Crushed tissue was transferred to a 1.5 mL microcentrifuge
tube and 500 .mu.L of Lysis buffer (Cell Signaling Technologies,
Cat No. 9803) with protease inhibitor (Roche, Cat No. 11836153001)
was added and incubated on ice for 30 min with frequent vortexing.
The sample was then centrifuged at 16000 g for 10 min. The
supernatant was collected and sent for protein array analysis by
Aushon Biosystems. For tissue culture, one 7.3 cm.sup.2 piece of
membrane was plated onto a well of a 12-well dish and 2 mL of
DMEM+1% HSA+ antibiotic/antimycotic were added and incubated at
37.degree. C..+-.2.degree. C. for 3, 7, or 14 days. After
incubation, tissue and culture media were transferred to a 15 mL
conical tube and centrifuged at 2000 rpm for 5 min. Culture
supernatant was collected and sent for protein array analysis by
Aushon Biosystems.
Example 18.3
Amniotic and Chorionic Membranes
[0451] Amniotic and chorionic membranes were isolated and packaged
at -80.degree. C..+-.5.degree. C. according to the manufacturing
protocols disclosed herein in Example 3. Packaged membranes were
then thawed in a 37.degree. C..+-.2.degree. C. water bath and
washed 3 times with DPBS. Membranes were cut into 8 cm.sup.2
pieces. For tissue lysates, one 8 cm.sup.2 piece of membrane was
snap frozen in liquid nitrogen followed by pulverization using a
mortar and pestle. Crushed tissue was transferred to a 1.5 mL
microcentrifuge tube and 500 .mu.L of Lysis buffer (Cell Signaling
Technologies, Cat No. 9803) with protease inhibitor (Roche, Cat No.
11836153001) was added and incubated on ice for 30 min with
frequent vortexing. Tissue lysate was then centrifuged at 16000 g
for 10 min. The supernatant was collected and sent for protein
array analysis by Aushon Biosystems. For tissue culture, one 8
cm.sup.2 piece of membrane was plated onto a well of a 12-well dish
and 2 mL of DMEM+1% HSA+ nantibiotic/antimycotic were added and
incubated at 37.degree. C..+-.2.degree. C. for 3, 7, or 14 days.
After incubation, tissue and culture media were transferred to a 15
mL conical tube and centrifuged at 2000 rpm for 5 min. Culture
supernatant was collected and sent for protein array analysis by
Aushon Biosystems.
[0452] Initial testing consisted of an analysis of 36 proteins that
are important for wound healing. The list of identified proteins is
described in Table 11.
TABLE-US-00011 TABLE 11 List of selected proteins for analysis.
Protein Group Based on Functionality Comments Metalloproteases
Matrix Metalloproteinase 1 Matrix and growth factor (MMP1),
MMP2,3,7,8,9,10,13 degradation; facilitate cell migration. MMP
Inhibitors Tissue Inhibitors of MMPs Have angiogenic activity;
(TIMP1 and 2) can be placed in the "angiogenic factors" group.
Angiogenic Factors Angiotensin-2 (Ang-2); basic Majority of these
factors Fibroblast Growth Factor also have growth and basic (bFGF);
heparin-bound migration stimulatory Epidermal Growth Factor
activities and can be (HB-EGF); EGF; FGF-7 (also placed in a group
of known as Keratinocyte growth factors. Growth Factor-KGF);
Platelet derived Growth Factors (PDGF) AA, AB, and BB; Vascular
Endothelial Growth Factor (VEGF), VEGF-C and VEGF-D; Neutrophil
gelatinase-associated lipocalin (NGAL); Hepatocyte Growth Factor
(HGF); Placenta Growth Factor (PIGF); Pigment Epithelium Derived
Factor (PEGF); Thrombopoetin (TPO) Protease Inhibitor/Protein
Alpha-2-macroglobulin Inhibit protease activity; Carrier regulate
growth factor activity. Growth Factors See "angiogenic factors" +
See "angiogenic factors." Transforming Growth Factor alpha (TGF-a)
Cytokines Adiponectin (Acrp-30) Affect keratinocyte functions.
Granulocyte Colony- Protection from infections. Stimulating Factor
(G-CSF) Interleukin1 Receptor Regulate activity of Antagonist
(IL-1RA) inflammatory cytokine IL- 1. Leukemia Inhibitory Factor
Support angiogenic (LIF) growth factors. Chemokines SDF-1beta
Attracts endothelial and other stem cells from circulation to wound
site. Regulators of IGF Insulin-like growth factor Regulate IGF
activity. binding protein (IGFBP1,2,3)
Example 18
Protein Expression in Present Placental Products
[0453] Preliminary protein array data analyses showed that the
majority of selected testing factors (refer to Table 11) were
expressed in amniotic membrane, chorionic membrane, Apligraf, and
Dermagraft. Three proteins were identified as unique for the
amniotic membrane and/or the chorionic membrane which are
undetectable in Apligraf and Dermagraft. These proteins are EGF,
IGFBP1, and Adiponectin. All three proteins are important for wound
healing. FIG. 13 depicts expression of EGF (A), IGFBP1 (B), and
Adiponectin (C) in amniotic or chorionic membranes. AM75 and AM 78
are placental products of the present invention (e.g.
cryopreserved), CM75 and CM78 are cryopreserved chorionic membrane
products. These proteins are believed by the inventors to
facilitate the therapeutic efficacy of the present placental
products for wound healing.
[0454] These data are consistent with certain embodiments of the
present invention that provide a placental product comprising an
amniotic membrane containing EGF, IGFBP1, and/or adiponectin
Example 19
Wound Healing Proteins are Secreted for a Minimum of 14 Days
[0455] Placental products of the present invention demonstrate a
durable effect, desirable for wound healing treatments. The
extracellular matrix and presence of viable cells within the
amniotic membrane described in this invention allow for a cocktail
of proteins that are known to be important for wound healing to be
present for at least 14 days. Amniotic membranes were thawed and
plated onto tissue culture wells and incubated at 37.degree.
C..+-.2.degree. C. for 3, 7, and 14 days. At each time point, a
sample of the culture supernatant was collected and measured
through protein array analysis as described in Example 18. Table 12
illustrates the level of various secreted factors in tissue culture
supernatants from two donors of amniotic membranes at 3, 7 and 14
days as measured through protein array analysis.
TABLE-US-00012 TABLE 12 Levels of proteins secreted in amnion
tissue culture supernatants at different time points (pg/ml). Day 3
Day 7 Day 14 hACRP30 548.03 766.73 371.56 hAlpha2Macroglobulin
69687.55 31764.00 48477.62 hANG2 0.00 9.28 1.65 hEGF 3.06 2.51 2.32
hbFGF 40.80 85.46 269.97 hFibronectin 1932101.25 3506662.00
6019286.50 hHBEGF 41.78 80.50 78.09 hHGF 5358.09 9327.67 18081.16
hIGFBP1 2654.57 6396.11 4666.88 hIGFBP2 4379.76 23797.46 21784.21
hIGFBP3 36030.52 107041.71 13350.99 hIL1ra 116593.20 675.09 4927.52
hKGF 7.29 13.86 36.59 hMMP1 323249.53 1727765.60 15272931.52 hMMP10
14804.44 20557.91 16194.56 hMMP13 92.92 408.17 399.01 hMMP2
38420.90 322500.72 3283119.13 hMMP3 66413.54 283513.74 3598175.53
hMMP7 128.51 147.65 4005.14 hMMP8 463.32 2109.21 2331.47 hMMP9
6139.53 25810.38 60483.67 hNGAL 15754.19 70419.63 721923.09 hPDGFAA
18.02 58.69 16.31 hPDGFAB 16.58 58.41 28.30 hPDGFBB 1.94 21.67 5.84
hPEDF 6793.74 21645.90 169990.84 hSDF1b 0.00 24.09 37.12 hTGFa
15.05 14.89 205.90 hTGFb1 334.07 341.53 680.33 hTGFb2 119.59 207.79
731.96 hTIMP1 197743.23 437492.21 247661.65 hTIMP2 4724.25 19970.76
189810.51 hTSP1 0.00 0.00 1274.62 hTSP2 13820.61 59695.21 991366.59
hVEGF 44.98 57.45 7.40 hVEGFC 548.03 766.73 371.56
Example 20
Interferon 2.alpha. (IFN-2.alpha.) and Transforming Growth
Factor-.beta.3 (TGF-.beta.3)
[0456] Placental products described in this invention have been
analyzed for the presence of IFN-2.alpha. and TGF-.beta.3. Briefly,
after thawing, the membranes were homogenized and centrifuged at
16,000 g to collect the resulting supernatants. Supernatants were
analyzed on a commercially available ELISA kit from MabTech
(IFN-2.alpha.) and R&D Systems (TGF-.beta.3). FIG. 14 shows
significant expression of IFN-2.alpha. (A) and TGF-.beta.3 (B) in
placental product homogenates.
[0457] Without being bound by theory, interferon-2.alpha. and
TGF-.beta.3 may aid in the prevention of scar and contracture
formation. IFN-2.alpha. may serve a role to decrease collagen and
fibronectin synthesis and fibroblast-mediated wound
contracture.
Example 21
Tissue Reparative Proteins in Amniotic Membranes
[0458] Placental product homogenates were analyzed for the presence
of proteins that are important in tissue repair.
[0459] Placental product described in this invention have been
analyzed for the presence of tissue reparative proteins. Briefly,
the thawed products were incubated in DMEM+10% FBS for 72 hrs. The
membranes were then homogenized in a bead homogenizer with the
culture media. The homogenates were centrifuged, and the
supernatants were analyzed on commercially available ELISA kits
from R&D Systems. FIG. 15 shows significant expression of
BMP-2, BMP-4, PLAB, PIGF, and IGF-1 in several donors of amniotic
membranes.
[0460] Without being bound by theory, the inventors believe that
efficacy of the present placental products for wound repair are
due, in part, to the role of BMPs, IGF-1, and PIGF in the
development and homeostasis of various tissues by regulating key
cellular processes. BMP-2 and BMP-4 may stimulate differentiation
of MSCs to osteoblasts in addition to promote cell growth;
placental BMP or PLAB is a novel member of the BMP family that is
suggested to mediate embryonic development. Insulin-like growth
factor 1 (IGF-1) may promotes proliferation and differentiation of
osteoprogenitor cells. Placental derived growth factor (PIGF) may
acts as a mitogen for osteoblasts.
Example 22
MMPs and TIMPs
[0461] Both MMPs and TIMPs are among the factors that are important
for wound healing. However, expression of these proteins must be
highly regulated and coordinated. Excess of MMPs versus TIMPS is a
marker of poor chronic wound healing. We investigated expression of
MMPs and TIMPs and its ratio in amniotic membrane and chorionic
membrane and compared it to the expression profile in Apligraf and
Dermagraft.
[0462] Results showed that all membranes express MMPs and TIMPs;
however, the ratio in the thawed placental products and chorionic
membranes is significantly lower. Therefore, these membranes will
be more beneficial for wound healing (FIG. 16).
[0463] Accumulated data indicate that the MMP to TIMP ratio is
higher in cases of non-healing wounds. For example, the ratio
between MMP-9 and TIMP1 is approximately 7-10 to one for good
healing and 18-20 or higher for poor healing. Analysis of the ratio
between MMPs and TIMPs secreted by placental tissues, Apligraf, and
Dermagraft showed that the amniotic and chorionic membrane products
contain MMPs and TIMPs at an approximate ratio of 7, which is
favorable for wound healing. In contrast, Dermagraft had a
ratio>20, and Apligraf had a ratio>200.
[0464] These data are consistent with certain embodiments of the
present invention that provide a placental product comprising an
amniotic membrane containing MMP-9 and TIMP1 at a ratio of about
7-10 to one.
Example 23
.alpha.2-Macroglobulin
[0465] .alpha.2-macroglobulin is known as a plasma protein that
inactivates proteinases from all 4 mechanistic classes, serine
proteinases, cysteine proteinases, aspartic proteinases, and
metalloproteinases. Another important function of this protein is
to serve as a reservoir for cytokines and growth factors, examples
of which include TGF, PDGF, and FGF. In the chronic wounds like
diabetic ulcers or venous ulcers, the presence of high amount of
proteases leads to rapid degradation of growth factors and delays
in wound healing. Thus, the presence of .alpha.2-macroglobulin in
products designed for chronic wound healing will be beneficial.
Results of the protein array analysis showed that amniotic and
chorionic membranes contain .alpha.2-macroglobulin (Table 13).
Although these preliminary data show high variability between
donors, the importance of this protein in wound healing prompted
the additional evaluation of .alpha.2-macroglobulin in placental
tissues using a single analyte ELISA instead of protein array,
which is a useful tool to evaluate the presence of multiple
proteins in one sample for profiling.
[0466] These data are consistent with certain embodiments of the
present invention that provide a placental product comprising an
amniotic membrane containing .alpha.2-macroglobulin.
TABLE-US-00013 TABLE 13 Expression of .alpha.2-macroglobulin in
placental tissue protein extracts. .alpha.2-macroglobulin Sample
(pg/mL/cm.sup.2) AM75 7 CM75 790 AM78 53042 CM78 1014
Example 24
Establishment of EGF as a Marker for Amniotic Tissue Potency
[0467] EGF is among the factors that are important for wound
healing (Schultz et al., 1991, Komarcevic, 2000, and Hong et al.,
2006). The absence or decreased amount of EGF is one characteristic
of chronic wounds (Harding et al., 2002). Evaluation of proteins
derived from amniotic membrane samples prepared according to the
developed manufacturing process disclosed by the present
application reveal that EGF is one of the major factors secreted in
higher quantities by these tissues. The importance of EGF for wound
healing together with high levels of EGF detected in the presently
disclosed amniotic membranes support selection of EGF as a potency
marker for evaluation of membrane products manufactured for
clinical use pursuant to the present disclosure. A commercially
available ELISA kit from R&D Systems was selected for
evaluation of its suitability to measure EGF secreted by amniotic
membranes. ELISA qualification meets the standards established by
the FDA and ICH guidances for bioanalytical assay validation
(Validation of Analytical Procedures: Text and Methodology Q2(R1),
1994; ICH Harmonized Tripartite Guideline and Guidance for Industry
Bioanalytical Method Validation, 2001). Amniotic membranes
evaluated for expression of EGF by this method confirmed protein
array data and further demonstrated that EGF was a unique factor
expressed at clinically significant levels in these tissues.
Example 25
Amniotic Tissue Expression of EGF
[0468] Protein array analysis provided initial evidence that EGF
was uniquely expressed in amniotic membranes but not in chorionic
membranes (Table 14). The levels of EGF measured in amniotic
membranes were of clinical significance.
TABLE-US-00014 TABLE 14 Protein array data showing range of
expression of EGF in amniotic and chorionic membranes from multiple
donors. Amnion Chorion (pg/ml) (pg/ml) EGF 127.3-361.4 0-0.8
[0469] These data are consistent with certain embodiments of the
present invention that provide a placental product comprising an
amniotic membrane containing EGF, optionally in substantial
amounts.
Homogenate of Placental Products
[0470] Placental products were thawed until no remaining frozen
cryomedia was present. Membranes were then removed from bags and
cut into 4 cm.times.2 cm pieces while still adhered to
nitrocellulose. Each piece of tissue was then removed from the
nitrocellulose and washed twice with PBS. Each tissue was then snap
frozen in a homogenization tube using liguid nitrogen.
Subsequently, one pre-cooled 5 mm steel bead was added to each
tube; samples were then homogenized using a Qiagen Tissue Lyser
according to the manufacturer's recommendations in 500 .mu.L
homogenization media. Tissue homogenates were stored at -80.degree.
C..+-.5.degree. C. until analyzed by ELISA for EGF expression.
ELISA Procedure and Validation
[0471] Samples were analyzed for the expression of EGF using the
Quantikine Human EGF ELISA Kit (R&D Systems) according to the
manufacturer's recommendations. Several parameters were tested to
establish the test criteria and to show the suitability of this
ELISA kit to measure EGF in placental tissue samples. Assay
performance was assessed by analyzing linearity, range, lower and
upper limits of quantitation (LLOQ and ULOQ), precision, accuracy,
and robustness. Experimental data (Table 14) showed that the
quantitation range of this assay was 3.9-250 pg/mL EGF. The intra-
and inter-assay CVs ranged from 1.22 to 5.80% and 2.73 to 7.53%,
respectively. Additionally, sample recovery analysis demonstrated
accuracy within 20%. Furthermore, this assay showed dilutional
linearity and specificity. Ruggedness was also demonstrated by
assay insensitivity to variations introduced by different
analysts.
TABLE-US-00015 TABLE 15 Established ELISA parameters for measuring
EGF in placenta homogenates. Calibration Standard 3.9-250 pg/mL
Range Assay Quantitation 7.8-250 pg/mL Range LLOQ 7.8 pg/mL LOD
2.18 pg/mL ULOQ 250 pg/mL
EGF Expression in Amniotic Membranes
[0472] Measurement of EGF in amniotic preparations has proven to be
both reliable and reproducible. Measurement of EGF in multiple
donors showed that this method of quantification was a valuable
means of evaluating potency in tissue prepared pursuant to the
present disclosure for use in a clinical setting. FIG. 17 shows
representative expression of EGF in a thawed placental product and
chorionic membrane prepared and analyzed by the methods described
above. Results have been reproduced in multiple tissue
preparations.
[0473] These data are consistent with certain embodiments of the
present invention that provide a placental product comprising an
amniotic membrane containing EGF.
Example 26
Placental Tissues Enhance Cell Migration and Wound Healing
[0474] The process of wound healing is highly complex and involves
a series of structured events controlled by growth factors
(Goldman, 2004). These events include increased vascularization,
infiltration by inflammatory immune cells, and increases in cell
proliferation. The beginning stages of wound healing revolve around
the ability of individual cells to polarize towards the wound and
migrate into the wounded area in order to close the wound area and
rebuild the surrounding tissue. Upon proper stimulation, several
different types of cells including epithelial, endothelial,
mesenchymal, and fibroblastic cells are implicated in the wound
healing process (Pastar et al, 2008 and Bannasch et al., 2000).
Specifically, they proliferate and migrate into the wound area to
promote healing. Therefore, experiments were conducted to determine
if factors secreted from amniotic and chorionic membranes produced
pursuant to the present disclosure promote cell migration and wound
field closure. To accomplish this, a commercially available wound
healing assay (Cell Biolabs) and a highly accepted human
microvascular endothelial cell line (HMVEC, Lonza Inc.) were
utilized. Results indicated that cell migration was enhanced by
treatment with conditioned media from the placental membranes.
In Vitro Cell Migration Assay
[0475] Human microvascular endothelial cells (HMVECs) were grown
under normal cell culture conditions in defined complete media
(Lonza Inc.). To assess migration and wound field closure, a
commercially available wound healing assay was used (Cell
Biolab).
[0476] FIG. 18 depicts the Cell Biolabs 24-well Cytoselect wound
healing assay. (Figure reproduced from Cell Biolabs).
[0477] Cells were collected via trypsinization, pelleted, and
counted before being resuspended in complete media at a density of
2.times.10.sup.5 cells/mL. 250 .mu.L (5.times.10.sup.4 cells) cell
suspension was then pipetted into each side of a well containing a
wound healing insert (Cytoselect 24-well Wound Healing Assay Plate,
Cell Biolabs). The cells were grown for 24 hours in complete media.
After 24 hours, the wound inserts were removed. At the same time,
complete media was removed and replaced with experimental media.
Complete media and basal media were used as positive and negative
controls, respectively. To generate experimental media, placental
membranes were incubated for 3 days in DMEM with 1% human serum
albumin (HSA) in a tissue culture incubator. The resulting tissue
and media were then placed in eppendorf tubes and spun at high
speed in a microcentrifuge. The supernatants were collected and
stored at -80.degree. C..+-.2.degree. C. until use. For migration
and wound healing studies, conditioned media from placental
membranes was diluted 1:20 in basal media before being added to
experimental wells. After 18 hours, the media was removed, and the
cells were fixed for 20 min in 4% paraformaldehyde and stained with
crystal violet. The wound field in each well was then photographed.
Wound healing was determined by the amount of wound field still
visible at the end of the experiment when compared to control
pictures taken before conditioned media was added to the wells.
Placental Membrane Conditioned Media Supports Cell Migration and
Wound Field Closure
[0478] Conditioned media from amniotic and chorionic membranes was
used to assess the potential for these membranes to promote cell
migration and wound field closure. Conditioned media from placental
amniotic, chorionic, and a combination of amniotic/chorionic
membranes supported migration of cells into the experimental wound
field.
[0479] FIG. 19 depicts representative images of cells treated with
5% conditioned media from amniotic, chorionic, or a combination of
amniotic/chorionic tissue as well as positive and negative
controls. Wound field is 0.9 mm in width.
[0480] The ability of factors from placental membranes produced
pursuant to the present disclosure to promote HMVEC migration
indicated that these tissues have the ability to enhance wound
healing. Additionally, based on the insight of the inventors, it
has been surprisingly discovered that these tissues also enhance
revascularization since the HMVEC cell line is derived from
vascular endothelial cells.
[0481] These data demonstrate that placental products of the
present invention produce unexpectedly superior levels of factors
that promote wound healing therapies.
Example 27
Biochemical Profile of the Supernatants from Exemplary Placental
Tissue Products
[0482] Table 16 depicts the biochemical profile of the supernatants
of examplary placental products of the invention (results adjusted
per cm.sup.2 after subtraction of the negative background).
TABLE-US-00016 TABLE 16 Factors in Placental Tissue Product
(pg/cm.sup.2). Units Apligraf Dermagraft AM75 CM75 AM78 CM78 hMMP1
pg/ml/cm.sup.2 1964945.37 14818.20 2821.85 3531.81 117326.89 95.46
hMMP7 pg/ml/cm.sup.2 911.54 0.00 0.00 0.00 3.96 0.00 hMMP10
pg/ml/cm.sup.2 0.00 0.00 113.94 0.00 0.00 0.00 hMMP13
pg/ml/cm.sup.2 21.61 0.00 0.00 0.00 0.71 0.00 hMMP3 pg/ml/cm.sup.2
208281.70 180721.52 170.26 161.52 8325.17 0.00 hMMP9 pg/ml/cm.sup.2
8872.28 19321.39 214.78 1455.11 630.56 57.59 hMMP2 pg/ml/cm.sup.2
153341.77 19712.21 287.14 37.93 3823.38 24.44 hMMP8 pg/ml/cm.sup.2
36.92 12.19 0.00 0.00 0.00 0.00 hTIMP1 pg/ml/cm.sup.2 2487.18
10909.84 569.23 883.05 28743.48 97.94 hTIMP2 pg/ml/cm.sup.2 7285.53
1796.56 89.29 13.72 424.06 4.83 MMP/TIMP 239.26 19.72 6.81 6.26
4.50 2.62
Example 28
Biochemical Profile of the Lysates from Exemplary Placental Tissue
Products
[0483] Table 17 depicts the biochemical profile of the lysates of
examplary placental tissue products of the invention (results
adjusted per cm.sup.2 after subtraction of the negative
background).
TABLE-US-00017 TABLE 17 AM75 lysate AM78 lysate CM75 lysate CM78
lysate pg/ml pg/ml pg/ml pg/ml hACRP30 50.8 1154.6 1213.7 225.3
hAlpha2- 1910.6 426191.6 8174.4 9968.6 Macroglobulin hEGF 127.3
361.4 0.0 0.8 hbFGF 119.1 821.5 375.0 351.3 hGCSF 0.7 3.2 1.2 0.7
hHBEGF 127.5 168.0 15.4 84.5 hHGF 3943.7 15060.0 29979.6 50392.8
hIGFBP1 5065.0 9456.6 934.0 1443.6 hIGFBP2 12460.8 5569.7 135.9
134.6 hIGFBP3 50115.7 41551.4 4571.5 11970.2 hIL1ra 3881.0 32296.9
5168.2 525.5 hKGF 1.4 8.8 3.1 1.5 hLIF 0.0 4.2 0.0 0.0 hMMP1 9144.1
20641.2 2882.9 6582.3 hMMP10 0.0 15.5 79.3 87.5 hMMP2 2067.3 4061.9
949.5 748.8 hMMP3 0.0 36.2 0.0 0.0 hMMP7 5.1 11.4 4.5 9.1 hMMP8 0.0
0.0 0.0 0.0 hMMP9 92.2 2878.1 2676.2 1259.3 hNGAL 6900.1 6175.9
938.5 229.7 hPDGFAA 0.0 12.5 39.8 35.2 hPDGFAB 11.2 31.3 14.4 14.0
hPDGFbb 4.6 13.4 4.0 1.3 hPEDF 0.0 652.6 0.0 0.0 hTIMP1 7958.1
35955.6 50712.3 17419.9 hTIMP2 3821.8 7443.2 640.7 780.0 hVEGF 3.3
11.8 125.2 8.4 hVEGFC 46.5 150.0 123.5 51.7 hVEGFD 25.7 31.0 15.0
20.4
Example 29
Use of Placental Products for Treating Diabetic Foot Ulcers
[0484] Purpose: Despite bioengineered skin substitutes that contain
human fibroblasts or a combination of human fibroblasts and
keratinocytes, published rates of chronic wound healing remain low,
with approximately half of all wounds recalcitrant to even these
newer therapies. Morbidity and mortality from diabetic foot
ulceration are substantial as the 5 year mortality rate following a
lower extremity amputation is between 39% and 68%. (Page J. J of
Foot & Ankle Surgery 2002; 41(4):251-259; Isumi Y., et al.
Diabetes Res and Clin Practice 2009; 83:126-131).
[0485] A instant membrane product, which provides necessary
angiogenic and anti-inflammatory growth factors was introduced in
an effort to improve outcomes of patients with chronic skin
ulceration at-risk for amputation.
[0486] Objective: Patients with chronic diabetic foot ulceration,
unresponsive to available therapy and at-risk for amputation were
considered for treatment. All wounds were aggressively debrided
prior to graft application. Patients were evaluated regularly and
application of a membrane product of the present invention was at
the discretion of the treating physician. Offloading was encouraged
in both patients.
Introduction
[0487] According to the United States Food and Drug Administration
(FDA), a chronic, cutaneous ulcer is defined as a wound that has
failed to proceed through an orderly and timely series of events to
produce a durable structural, functional and cosmetic closure(2).
The most common chronic wounds include pressure ulcers and leg
ulcers. The triad of peripheral neuropathy, deformity, and minor
trauma has emerged as the most frequent causes of insult that lead
to foot ulcerations. In terms of healing rates, an appropriate
benchmark for a chronic wound is a decrease of 10% to 15% in size
every week, or 50% decrease in size over a one-month period. A
three-year retrospective cohort study performed by Ramsey et al. of
8,905 patients in a large health maintenance organization who have
diabetes reported a 5.8% cumulative incidence of ulceration. At the
time of diagnosis, 15% of these patients developed osteomyelitis
and 16% required partial amputation of a lower limb.
[0488] Approximately 80% to 85% of lower extremity amputations are
preceded by foot ulcerations. Morbidity and mortality from diabetic
foot ulceration are substantial as the 5 year mortality rate
following a lower extremity amputation is between 39% and 68%. (2).
These mortality rates are higher than the five-year mortality rates
for breast cancer, colon cancer, and prostate cancer.
[0489] Despite all of the advances in bioengineered tissue for the
treatment of chronic diabetic ulcerations, there are an abundance
of patients whose ulcerations are resistant to therapy, and result
in a chronic wound. Because of healing rates that only approach 50%
with these newer therapies, the use of stem cells in regenerative
medicine has been of particular interest recently. The ultimate aim
is to promote restoration of functional skin. A preliminary study
was performed by Fiami et al. in which they isolated mesenchymal
stem cells from umbilical cord blood and inoculated them onto a
piece of de-epithelialized dermis. The results of this preliminary
study showed that peripheral stem cells are capable of surviving
and expressing neoangiogenesis. In addition to showing promise for
tissue repair, mesenchymal stem cells exhibit low immunogenicity
and can be transplanted universally without having to undergo
compatibility testing between the donor and recipient.
[0490] In this study, clinical evidence of remarkable healing using
an instant membrane product for the treatment of two chronic wounds
that amputation was considered. The fundamentals of wound
management are still the cornerstone of comprehensive wound care in
any treatment protocol including adequate debridement, offloading,
maintaining a moist environment, and adequate perfusion and
infection control.
Materials
[0491] An instant membrane product was made as taught herein,
comprising an allograft derived from the aminon comprising a
bilayer of native epithelial cells on a basement membrane and a
stoma layer consisting of neonatal fibroblasts, extracellular
matrix (ECM) and mesenchymal stem cells (MSC).
Limb Salvage: Case One
History and Physical Examination
[0492] A 70 year old male presented to the emergency department
with bulla formation on the dorsolateral aspect of his right foot
between the fourth and fifth digits, edema and pain, and a small
lesion lateral to the fifth digit. The patient reported a history
of minor trauma to the area two weeks prior to presentation. The
patient had a history of type II diabetes mellitus, hypertension,
heart failure, chronic obstructive pulmonary disease, and chronic
kidney disease treated with hemodialysis three times a week. The
patient had a surgical history of an aorta-venous graft
replacement. He denied any history of alcohol, tobacco or drug use.
Physical exam revealed no active purulent drainage or malodor, and
no tenderness on palpation. The vascular exam revealed non-palpable
pulses in the dorsalis pedis and posterior tibial arteries. Doppler
exam revealed a monophasic dorsalis pedis pulse with a biphasic
posterior tibial artery pulse. The fifth digit had gangrenous
changes and was cold on palpation. There were ischemic changes of
the fourth digit. Radiographic evaluation revealed scattered air
densities indicative of soft tissue gas in the fourth interspace as
well as the tip of the fifth digit.
Preoperative Management
[0493] The patient was started on intravenous antibiotics of
vancomycin and piperacillin and tazobactam at appropriate renal
dosing.
Operative Management
[0494] The patient was taken to the operating room where an
incision and drainage of the fourth interspace was performed, and a
partial fifth ray amputation to the level of the metatarsal head
was performed without complication. The wound was left open and
packed with sterile gauze moistened with sterile normal saline, and
covered with a sterile compressive dressing. Intraoperative
findings revealed liquefactive necrosis of surrounding tissues with
purulence and malodor. The patient underwent 2 subsequent surgical
debridements, with the second resulting in further removal of the
fourth and fifth metatarsal shafts. In a third surgery further
debridement of necrotic soft tissue and amputation of the fourth
digit was performed. On May 20, 2010 treatment with an instant
membrane product was initiated. Prior to the graft placement the
patient had undergone successful recanalization of the popliteal
artery and the peroneal artery without significant residual
stenosis.
Postoperative Course
[0495] The patient followed up with his podiatric surgeon within 2
days of being discharged from the hospital. Upon initial exam,
there were no clinical signs of infection, and the proximal dorsal
incision appeared coapted. The third digit was dusky and cool in
appearance. Radiographs were taken which showed no evidence of soft
tissue gas or acute osteomyelitis. A dry sterile dressing was
applied. The patient received applications of the insant membrane
product at 6 additional visits in an outpatient office. Prior to
each application the wound was evaluated for abscess, cellulitis,
drainage, hematoma formation, and infection. At each visit, the
wound decreased in size and appeared more granular in nature as
compared to previous visits. At the time of the third application
the wound had decreased in size 50%.
[0496] At 19 weeks the wound was considered closed, and the patient
was instructed to remain weight bearing on the affected limb with
the use of a surgical shoe only.
[0497] Photographs of the remarkable wound healing mediated by a
placental product of the present invention as shown in FIG. 20.
Panel A: First application of an instant membrane product; B: 8
weeks post first an instant membrane product application; C: 10 1/2
weeks post first an instant membrane product application; D: 12
weeks post first an instant membrane product application; E: 19
weeks post first an instant membrane product application.
Limb Salvage: Case Two
History and Physical Examination
[0498] A 44-year old male presented to an outpatient office with a
large ulceration on the plantar aspect of his left hallux,
secondary to a previous trauma a few weeks prior to the visit. The
patient had a history of diabetes mellitus for the past five years
complicated by peripheral neuropathy, hypertension, dyslipidemia,
and osteomyelitis. Past surgical history included abdominal aortic
aneurysm repair and circumcision. On physical exam the ulceration
measured 4.0 cm.times.2.0 cm.times.1.5 cm, probing to the distal
phalanx with exposed tendon. There was no ascending cellulitis or
lymphangitis, and no increased temperature gradient. Capillary fill
time, hair growth, and tissue turgor were all normal. There were
palpable pulses in the dorsalis pedis and the posterior tibial
artery. Radiographic exam was negative for soft tissue gas.
Magnetic resonance imaging revealed osteomyelitis in the distal
aspect of the proximal phalanx and the distal phalanx of the great
toe with a small soft tissue abscess in the region of the dorsal
soft tissue adjacent to the distal phalanx.
Preoperative Management
[0499] The patient was started on intravenous antibiotics. He was
taken to the operating room for excisional debridement of all
nonviable tissue and application of the instant membrane
product.
Operative Management
[0500] The ulceration was debrided to healthy tissue with
utilization of both sharp dissection and Versajet.TM., leaving the
head of the proximal phalanx exposed plantarly. The instant
membrane product was then placed over the wound bed and exposed
bone. The patient tolerated the procedure without complication. The
patient was discharged from the hospital the day after surgery on a
five week course of intravenous antibiotic therapy.
Postoperative Course
[0501] The patient was instructed to remain strictly non-weight
bearing to the affected limb, and returned for follow-up on
post-operative day 6. The dressing was clean, dry and intact. There
were no post-operative complications such as abscess, cellulitis,
discomfort, or drainage and no clinical signs of infection. The
patient received a total of 7 stem cell graft applications over the
course of the next 8 weeks. At each visit the wound was inspected
for clinical signs of infection. Evaluation at each visit revealed
marked development in granulation tissue to the wound base and
significant decrease in size. Eight weeks after the initial
application of the allograft tissue the wound was closed.
[0502] Photographs of the remarkable wound healing mediated by a
placental product of the present invention as shown in FIG. 21.
Panel A: Osteomyelitis, tendon exposed, probed to bone. First stem
cell graft was applied after surgical debridement; B: Status post 1
application of stem cell graft, wound is granular in nature and no
signs of infection; C: 3 weeks post surgical intervention; 2
applications on the instant membrane product, the wound is
considerably smaller in circumference and depth; D: 6 weeks post
surgical intervention the wound is almost closed; E: 8 weeks and 7
applications of the instant membrane product, the wound is
closed.
Conclusion
[0503] Despite the tremendous progress in skin tissue engineering
in the past few decades, current therapy has limited efficacy in
the treatment of chronic diabetic ulceration. As shown in this case
report of two patients, the use of advanced therapies containing
stem cells may prove useful to ultimately heal these patients in
lieu of amputation, reduce mortality rates, and at the same time be
a cost effective alternative to standard treatments currently on
the market. Both patients highlighted in this case report received
7 applications of a membrane product of the present invention.
Complete healing occurred in both patients. There were no reported
complications associated with treatment; the instant membrane
product was safe and effective in an initial evaluation of two
patients with diabetic foot ulceration at-risk for amputation.
These results indicate that patients with recalcitrant, chronic
wounds should be considered for this novel therapy.
* * * * *